# o2h group

> Seeding new ideas in science, technology and green innovation


## Posts

- [o2h Group Marks 20 Years with the 7th o2h Collaborative Innovation Conference](https://o2h.com/press-release/o2h-group-marks-20-years-with-the-7th-o2h-collaborative-innovation-conference/): The 7th o2h Collaborative Innovation Conference successfully concluded at the Hyatt Regency Ahmedabad, bringing together a distinguished lineup of experts from diverse sectors. The event marked the 20th anniversary of the o2h Group, celebrating two decades of pioneering work in innovation, investment, and entrepreneurship in life sciences and tech. The conference featured thought-provoking panel discussions on key global and national issues, including India’s economic outlook following Trump’s tariffs, the rise of Artificial Intelligence (AI) agents, the growing obesity crisis, and the impact of ongoing geopolitical conflicts. The event also hosted two compelling keynote sessions—one by Renu Pokhrana, founder of India Recycles, […]
- [Finalist for 'Best Performing R&D Service Provider of the Year' at ON Awards 2024](https://o2h.com/discovery/finalist-for-best-performing-rd-service-provider-of-the-year-at-on-awards-2024/): We are excited to announce that o2h discovery was the Finalist in the prestigious ‘Best Performing R&D Service Provider of the Year’ at ON Awards 2024 organised by One Nucleus, a not-for-profit Life Sciences & Healthcare organisation. The ‘Best Performing R&D Service Provider of the Year‘ category acknowledges organisations that have demonstrated remarkable achievements in the field of drug discovery services. This recognition highlights our dedication to providing outstanding drug discovery research services that drive innovation and progress within the biotech industry. The evaluation process for this esteemed category took into consideration various aspects, including business performance, customer service performance, […]
- [o2h group hosts the 6th o2h Collaborative Innovation Conference](https://o2h.com/events/6th-edition-o2h-collaborative-innovation-conference/): The conference served as a platform for stimulating discussions, idea exchange, and networking opportunities to facilitate collaborative innovation. Ahmedabad: o2h Group, based out of Ahmedabad, India and Cambridge, UK, a leading investor in emerging life science and tech companies, hosted the 6th o2h Collaborative Innovation Conference in Ahmedabad, bringing together participants from diverse sectors. The conference served as a platform for stimulating discussions, idea exchange, and networking opportunities aimed at facilitating collaborative innovation. The conference witnessed engaging sessions and stimulating discussions on an array of topics including free trade, the role of India in the global biotech ecosystem, advancements in […]
- [ChamelogK Assay: Unveiling Chameleonicity for Protac Molecules](https://o2h.com/discovery/chamelogk-assay-unveiling-chameleonicity-for-protac-molecules/): PROTACs are providing a different way to modulate and treat a wide range of diseases through their ability to target protein degradation. A number of new players are actively engaged in harnessing the potential of PROTACs to create therapeutics with enhanced specificity and efficacy. This is helping to increase the tractability of previously challenging drug discovery targets. PROTACs generally sit outside Lipinski space, their mechanism of action requiring larger molecular weights and distinct physicochemical properties (beyond the Rule of Five, Ro5). While these characteristics hold promise for novel drug modalities, they present challenges, particularly in terms of permeability and bioavailability. […]
- [Boosting the success potential of promising Biotech Startups: the o2h kickstarter competition](https://o2h.com/discovery/boosting-the-success-potential-of-promising-biotech-startups-the-o2h-kickstarter-competition/): Biotech businesses benefit society by addressing unmet scientific and medical needs. However, there remains untapped potential for accelerating the market adoption of their breakthrough solutions. In the dynamic world of biotechnology, startups emerge as the pioneers of innovation, pushing the boundaries of scientific discovery. These prospective ventures bring new perspectives, game-changing novel drug/therapeutic concepts, and the development of novel chemical entities (NCEs) to the table. However, the path from concept to success is frequently loaded with difficulties for the small molecule based biotech startups. Recognizing this, the emphasis on increasing the viability of early stage biotech businesses has never been […]
- [Understanding the Dynamics of Surface Plasmon Resonance (SPR) in Biological Applications](https://o2h.com/discovery/dynamics-of-surface-plasmon-resonance-in-biological-applications/): Over the last two decades, Surface Plasmon Resonance (SPR) has evolved into a crucial label-free detection approach, revolutionising biomolecular interaction studies in clinical settings. This technology enables high-sensitivity real-time measurement of interactions without the use of labels. Label-free detection eliminates the requirement for specialised tags or dyes, allowing for more sensitive measurement of target analytes and the use of native biomolecules appropriate for biologically relevant methods. Since its introduction in the early 1990s, SPR has proven to be one of the most powerful technologies for determining specificity, affinity, and kinetic parameters during macromolecule binding in a variety of bonds, including protein-protein, protein-DNA, […]
- ["Empowering Targeted Protein Degradation with Protac Services: Unleashing the Power of E3 Ligases"](https://o2h.com/discovery/empowering-targeted-protein-degradation-with-protac-service/): Can you imagine a world in which we could selectively erase disease-causing proteins from our bodies, leaving healthy cells unaffected? This revolutionary concept is not science fiction; it’s the promise of targeted protein degradation (Protac Services), a cutting-edge approach that holds the potential to transform medicine as we know it. Targeted Protein Degradation (TPD) with it’s PROTAC Services, promisingly offers a novel way to eliminate toxic or disease-associated targets from cells. New medicines are being developed that leverage the cell’s intrinsic destruction machinery (ubiquitin-proteasome system), enabling them to surmount many of the conventional obstacles encountered in drug discovery. This empowering […]
- [How o2h Kickstarter Is Empowering Early Stage Biotech Startups: Addressing Key Challenges Head-On](https://o2h.com/discovery/how-o2h-kickstarter-empowering-biotech-startups/): Some of the challenges faced by biotech startups: Early-stage biotech startups often face a range of challenges, from limited funding and complex regulatory and inventory requirements to scientific hurdles, intense competition, time and resource management. The complexities of drug development and the highly competitive nature of the biotech industry make it challenging for startups to navigate these hurdles successfully, leading to possible setbacks and delays in reaching their milestones. All these biotech startup challenges can possibly affect their progress to the next milestone in their drug discovery journey. Moreover, the need for innovation and differentiation in a crowded market can […]
- [CITC won the "Best Use of technology" award in Pharma Industry Awards UK](https://o2h.com/discovery/citc-best-use-of-technology-award-in-pharma-industry-awards/): CITC (Chemistry in the Cloud)TM has won the “Best Use of Technology Award” o2h discovery is absolutely thrilled to announce that our in-house built proprietary app CITC (Chemistry in the Cloud)TM has won the category “Best Use of Technology Award” in the Pharma Industry Awards UK 2023. 🏆 The Pharma Industry Awards UK 2023 is dedicated to identifying and celebrating the most original and innovative individuals and companies that demonstrate excellence in the UK pharma industry. The awards cater to entrants ranging from researchers and marketing strategists to process and formulation engineers, from campus start-ups to the biggest names in the […]
- [Meet the o2h kickstarter evaluation committee members…](https://o2h.com/discovery/the-o2h-kickstarter-evaluation-committee-members/): We have recently announced the launch of the 5th edition of o2h kickstarter, exclusively to support USA-based early-stage biotech companies to boost their drug discovery program. The  competition is Live now and the last date to apply is October 10th… The aim of the o2h kickstarter 5.0 is to support the next wave of USA based biotechnology companies that have secured initial funding, have exciting drug targets, and have the ability to scale, but need expert services to supercharge their chemistry efforts to meet the next scientific and funding milestones.  Meet the o2h kickstarter evaluation committee members… The o2h kickstarter […]
- [o2h kickstarter 5.0 for early stage USA biotech](https://o2h.com/topics/drug-discovery/o2h-kickstarter-5-0-for-early-stage-usa-biotech/): Building on the success of our earlier kickstarter competition in the UK, Australia, Israel, and Italy, we are excited to announce the launch of the 5th edition of o2h kickstarter, exclusively tailored for early-stage biotech companies based in the USA. o2h discovery has now supported many companies through launching its Discovery kickstarter competition in several of the world’s most exciting biotech clusters, and now we aim to bring our biotech start-up machinery to the largest and most successful biotech ecosystems in the world, the USA. o2h discovery has been working with Venture Capital and early-stage biotech companies in the USA […]
- [o2h discovery launches ‘o2h kickstarter competition 5.0’ to support American early stage biotechs’](https://o2h.com/press-release/launching-kickstarter-for-early-stage-usa-biotech/): o2h discovery, a preclinical Contract Research Organization which has integrated drug discovery capabilities operating from its state-of-the-art research facilities in Ahmedabad, India and Cambridge, UK, is pleased to announce the fifth edition of the o2h kickstarter competition exclusively aimed towards supporting early-stage biotech companies based in the United states. US Biotech startups have always stayed at the forefront of innovation, revolutionising healthcare. Their journey involves cutting-edge research, leveraging AI and precision medicine, to develop transformative drugs. Their focus on rare diseases, gene therapies, and personalised medicine showcases a promising future where science and compassion converge, bringing life-changing treatments to those […]
- [o2h discovery is participating in the SCI-RSC 22nd Medicinal Chemistry Symposium](https://o2h.com/events/sci-rsc-22nd-medicinal-chemistry-symposium/): Meet o2h discovery’s Medicinal Chemistry team at booth 18, at the SCI-RSC 22nd Medicinal Chemistry Symposium We are excited to be participating in the SCI-RSC 22nd Medicinal Chemistry Symposium scheduled from 10-13 September, 2023 at Churchill College, Cambridge, UK.  Medicinal chemistry plays a crucial role in today’s healthcare landscape by serving as the bridge between chemistry and medicine, facilitating the design and development of pharmaceutical compounds that target specific diseases and conditions. This interdisciplinary field combines chemistry, biology, and pharmacology to optimize molecules for precise biological targets, often leveraging computational techniques for efficiency.  Its ongoing innovation remains essential in addressing ever-evolving […]
- [o2h discovery is in the finals for 'Most Impactful CRO' at OBN Awards 2023](https://o2h.com/press-release/o2h-discovery-is-in-the-finals-for-most-impactful-cro-at-obn-awards-2023/): Cambridge, UK: We are excited to announce that o2h discovery is the finalist for the Most Impactful CRO award at the OBN Awards 2023. The ‘Most Impactful CRO’ category acknowledges organisations that have demonstrated remarkable achievements in the field of drug discovery services. Our inclusion as a finalist highlights our dedication to providing outstanding drug discovery research services that drive innovation and progress within the biotech industry. The evaluation process for this esteemed category took into consideration various aspects, including: Business Performance: Assessing our consistent growth and impact of our services on the Biotech and Pharmaceutical market. Strategic R&D Impact: Recognizing […]
- [CITCᵀᴹ - Finalist in Pharma Industry Awards UK 2023](https://o2h.com/discovery/citc-finalist-in-pharma-industry-awards-uk/): o2h discovery is delighted to share that our in-house built proprietary app CITC (Chemistry in the Cloud)TM has been shortlisted as a finalist in the category “Best Use of Technology Award” in the Pharma Industry Awards UK 2023. 🏆   The Pharma Industry Awards UK 2023 is dedicated to identifying and celebrating the most original and innovative individuals and companies that demonstrate excellence in the UK pharma industry. The awards cater to entrants ranging from researchers and marketing strategists to process and formulation engineers, from campus start-ups to the biggest names in the Pharmaceutical industry. The Pharma Industry Awards UK […]
- [o2h co-work labs wins the award for Excellence in Adaptive Reuse by I2SL](https://o2h.com/co-work-labs/award-for-excellence-in-adaptive-reuse-by-i2sl/): Delighted to share that o2h co-work labs has won the award for Excellence in Adaptive Reuse by I2SL: International Institute for Sustainable Laboratories. The I2SL Go Beyond Awards is a unique program honoring organizations, individuals, products, and projects that are advancing sustainable, high-performance facilities. The project involved the renovation of a disused 300 year old building into an eclectic mixed use lab/office for seed stage companies. The design ethos combined an art meets science vibe, whilst maximising human collision for those serendipitous interactions which are the lifeblood of genuine innovation and creativity. We will be doing a tour at 3pm […]
- [Protai, a proteomics and AI-powered drug discovery startup wins the o2h kickstarter competition 3.0](https://o2h.com/discovery/protai-wins-the-o2h-kickstarter-competition-3-0/): Cambridge, UK: o2h discovery is delighted to announce Protai as one of the winners of the o2h kickstarter competition 3.0 which was exclusively launched to support exciting Israel biotechnology companies. Protai, based out of Tel Aviv and has developed a proteomics-centred, vertically integrated platform tailored for drug discovery. Protai has received backing from prominent venture capital funds, including Grove Ventures, Pitango HealthTech, and Maj Invest. Led by experienced entrepreneurs and tech executives, Eran Seger and Kirill Pevzner. Protai’s platform holds immense promise in accelerating drug discovery and advancing oncology research. As part of the kickstarter programme, o2h discovery will be […]
- [Biotech Bikers Special Edition with o2h group - July & August 2023](https://o2h.com/topics/art/biotech-bikers-special-edition-with-o2h-group-july-august/): The 10-day forecast looks great, and we hope for a lovely summer’s morning as we seek to embark on another fun biotech bikers ride, this time with a spicy twist for this July and August 2023! Join us for a series of special editions featuring unique biotech networking rides and valuable insights on Cambridge’s biotech cluster. The ride will be starting at 8:30 am from Mill SciTech Park, Hauxton, Cambridge on 29th July 2023. Sunil will be first up and give a short 10 min talk on unleashing the biotech potential of Cambridge, whilst you munch on freshly made ‘Aromi’ […]
- [PROTAC - o2h discovery's biology expertise](https://o2h.com/discovery/protac-services-biology/): PROTACs are heterobifunctional small molecules that can also target proteins previously thought of as “undruggable”. In the last few years, o2h discovery has developed strong expertise in the synthesis and screening of complex PROTAC molecules, and related specialty chemistry and Protac Services. We provide comprehensive solutions for designing and synthesis of PROTAC building blocks, linkers, compound libraries, and related intermediates to support Targeted Protein Degradation. PROTAC – o2h discovery’s biology expertise Our biology evaluation suite aims to help you estimate ternary complex formation and targeted protein degradation. Our team at o2h discovery has a customizable PROTAC toolbox™ kit of 150 […]
- [Entrepreneur Prashant Shah becomes NED at One Nucleus](https://o2h.com/press-release/entrepreneur-prashant-shah-becomes-ned-at-one-nucleus/): One Nucleus, the Cambridge based not-for-profit membership organisation for life science businesses, has recruited Prashant Shah, a serial DeepTech entrepreneur and investor as a Non-Executive Director. Prashant is co-CEO and co-founder of o2h group, leading the development of the Mill SciTech Park, supporting the creation of innovative life science and tech-bio companies. Prashant’s CV includes a current portfolio of positions including as chair of Form the Future CIC as well as board positions at the UK Science Park Association and DeepMirror. He is also a driving force behind community-focused initiatives such as Cambridge Wide Open Day, supporting the developments in the Life Science sector in sustainable […]
- [o2h discovery launches the o2h kickstarter competition 4.0 to support Italian early stage biotechs’](https://o2h.com/discovery/o2h-discovery-launches-the-o2h-kickstarter-competition-4-0/): Cambridge, UK, July 14th, 2023: o2h discovery, a preclinical Contract Research Organization which has integrated drug discovery capabilities operating from its state-of-the-art research facilities in Ahmedabad, India and Cambridge, UK, is pleased to announce the fourth edition of the o2h kickstarter competition exclusively aimed towards supporting early stage biotech companies based in Italy. o2h discovery has collaborated with several early stage biotech companies from Italy over the last 20 years. Italian biotech firms are making great strides towards developing novel therapies for unmet medical needs. The Italian biotech industry has undergone an extraordinary growth due to several factors, among them […]
- [Lipid Nanoparticles: o2h discovery's expertise in synthesizing phospholipid molecules to support LNP solutions for efficient drug delivery](https://o2h.com/discovery/lipid-nanoparticles-o2h-discovery-has-expertise-in-synthesizing-phospholipid-molecules/): In recent years, researchers and scientists have been increasingly exploring Lipid Nanoparticles, or LNPs, as a groundbreaking solution for drug delivery. These tiny, versatile carriers have the potential to revolutionise the field of medicine by overcoming several challenges posed by more traditional methods. Apart from drug delivery, LNPs are now being deployed in a variety of industries, including agriculture, nutrition, cosmetics, medical imaging, and other cutting-edge areas such as nanoreactors. LNPs, which gained significant attention for being an essential component of the COVID-19 mRNA vaccines, are pivotal for efficiently preserving and transferring mRNA to cells. In this comprehensive blog, we […]
- [First Cambridge Open Day is city-wide success for tech firms and local community](https://o2h.com/press-release/first-cambridge-wide-open-day/): The inaugural Cambridge Wide Open Day proved a great success last week, with science and technology companies opening their doors to connect the cluster with the local community, with a special emphasis on residents, pupils, students and jobseekers. Organizer Prashant Shah, co-founder of o2h group, said: “We were delighted with the outcome of the inaugural Cambridge Wide Open day. We had over 600 people register and 60-plus companies attending and venues participating.”   “There were a wide range of presentations, talks, product demos, clinics and tours from a wide range of companies small and large, covering a wide range of […]
- [‘UK science powerhouse’ opens its doors for the Cambridge Wide Open Day & Tour](https://o2h.com/press-release/launching-cambridge-wide-open-day/): Across the city, leading science companies and innovation parks will open their doors to showcase the cluster’s contribution to STEM innovation in the UK and strengthen its diverse, equitable and inclusive community. Life Sciences is one of the UK’s most successful sectors, worth over £94 billion to the UK economy in 2021, a 9% increase on the year before. Last week the Chancellor revealed a £650 million multi-faceted ‘Life Sci for Growth’ package to support economic growth and help deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills. Named a ‘UK science […]
- [o2h group supporting BiotechBikers's networking ride - June2023](https://o2h.com/uncategorized/o2h-group-supporting-biotechbikerss-networking-ride-june2023/): We are back with a summer ride in collaboration with Biotech Bikers this Saturday 10th June 2023 at 8:30 AM starting from Mill SciTech Park, Hauxton, Cambridge. Join this ride if you are a Biotechie and a cycling enthusiast for some networking and a fun ride. BiotechBikers is a global community that brings together biopharma, biotech, academic bioscience and healthcare professionals who share a passion for cycling. Mark Farmery, a biotech business developer and keen roadie based in Sweden, founded BiotechBikers in 2017 with the aim to bring together “bike-minded” pharma professionals in a unique networking community. Find the event agenda below: 08:30 […]
- [Targeted Protein Degradation/PROTAC Services: Revolutionizing the drug discovery approach with PROTAC molecules](https://o2h.com/discovery/targeted-protein-degradation/): PROTAC, also known as “PROteolysis-TArgeting Chimera,” is an emerging class of promising therapeutic small molecules. They are a heterobifunctional complex consisting of two terminal groups (ligand of the protein of interest (POI) and the particular ligand of E3 ubiquitin ligase) connected by a 5-15 atom linker. These molecules have potential advantages over conventional small molecule therapeutics as they are based on the concept of targeted protein degradation. Targeted Protein Degradation (TPD): Degradation of the target protein (Targeted Protein Degradation) is a new approach that has the potential to modulate disease indications and biological targets of interest that have historically been […]
- [o2h Kickstarter Newsletter: Chaitime Webinar](https://o2h.com/discovery/kickstarter-newsletter-chaitime-webinar/): Fifteen months ago we saw Rising Energy Prices, Interest rates increasing and the NASDAQ in full decline, while it is still choppy waters ahead, it feels like we are in a predictable cycle providing great comfort to investors. Early stage companies are always under pressure to reach their next milestone/hit their next target to gain access to more funding from various institutions such as VCs and government grants. To help address this challenge, in August 2022, we launched the o2h Kickstarter competition with the purpose of supporting early stage biotech companies that have secured initial funding, have exciting drug targets, […]
- [Psylo, a biotech company developing next-gen drugs for psychiatric disorders wins o2h kickstarter competition 2.0](https://o2h.com/discovery/psylo-wins-o2h-kickstarter-competition-2-0/): Cambridge, UK, May 4, 2023: o2h discovery is thrilled to announce Psylo as a winner of the o2h kickstarter competition 2.0. Psylo, a biotech company based in Sydney, Australia, is utilising artificial intelligence (AI) to develop a pipeline of next-generation psychedelic-inspired drug candidates that will target a variety of mental illnesses. As part of the kickstarter program, o2h discovery will be providing Psylo 6 FTE chemists for small molecule synthetic chemistry to support Psylo’s psychedelic-inspired NCEs research programme. Psylo is targeting the 5-HT2A receptor for the treatment of neuropsychiatric conditions based on the emerging promise of psilocybin. The company’s goal […]
- [o2h discovery launches 'the o2h kickstarter competition' to support Israeli early stage biotechs’](https://o2h.com/press-release/o2h-discovery-launches-the-o2h-kickstarter-competition-3-0/): Cambridge, UK, April 12th, 2023: o2h discovery, a preclinical Contract Research Organization which has integrated drug discovery capabilities in India and the UK, is pleased to announce the third edition of the o2h kickstarter competition exclusively aimed towards supporting early stage biotech companies based in Israel. o2h discovery has collaborated with several early stage biotech companies from Israel over the last 20 years. Israeli biotech firms are making great strides towards developing novel therapies for unmet medical needs. These firms are developing new opportunities to enhance human health and expand the field of biotechnology by harnessing cutting-edge technologies and concentrating […]
- [We are delighted to launch the first ever Cambridge Wide Open Day to drive inclusive collaboration](https://o2h.com/events/o2h-launches-first-ever-cambridge-wide-open-day/): o2h group, the creators of innovative SciTech communities, has launched the Cambridge Wide Open Day, offering a unique insight into the city best known as the ‘UK Centre of Science & Technology’. The inaugural event will take place on Wednesday 14 June 2023, welcoming science enthusiasts and local residents alike from across the Cambridge community – giving everyone the opportunity to explore the city’s world-class science and technology facilities all in one day. After setting up a new Department of Science, Innovation and Technology in February 2023, the UK government published its ‘International Technology Strategy’ last week. This new strategy sets […]
- [o2h group hosted 5th edition of the o2h Collaborative Innovation Conference in Ahmedabad](https://o2h.com/events/5th-edition-o2h-collaborative-innovation-conference/): Cambridge, UK, March 02 2023: The o2h group, a company based out of Ahmedabad, India and Cambridge, UK, which has a track record of nurturing and investing in emerging life science and tech companies, hosted the 5th edition of the o2h Collaborative Innovation Conference in Ahmedabad on Thursday. The conference brought together participants from the fields of science, technology, investment, and business for discussions on ways to enhance collaboration for innovation. The o2h collaborative innovation conference covered a range of topics, including investment strategies, decentralised science and blockchain, public policy, technology, business strategy, company responsibility, and more. The discussions at […]
- [Biiah, a tech startup committed to improving people's health through singing, wins the o2h tech kickstarter competition](https://o2h.com/technology/biiah-wins-the-o2h-tech-kickstarter-competition/): Cambridge, UK: We are thrilled to announce the second winner of the o2h tech kickstarter competition – Biiah! Biiah is a platform designed to help people establish a daily singing routine to improve their health, through virtual and in-person workshops as well as a companion app. Biiah helps businesses and communities support their employees’ health through group singing for health sessions throughout the workday. We are proud to support companies like Biiah, who are committed to making a positive impact on human health. At o2h technology, we understand the importance of innovative seed stage companies in the healthtech sector and […]
- [RouteZero, a greentech startup committed to decarbonising business travel wins the o2h tech kickstarter competition](https://o2h.com/technology/routezero-wins-o2h-tech-kickstarter-competition/): Cambridge, UK: We are thrilled to announce that Routezero is the first winner of the o2h tech Kickstarter competition! Routezero’s digital tools help corporations accelerate decarbonisation action by addressing the UK and Europe’s number one source of emissions, travel. As a seed stage green tech company, Routezero is committed to reducing carbon emissions and promoting sustainable practices, and we are excited to support them in their journey. At o2h technology, we understand that seed stage companies face a variety of barriers when it comes to designing, building, and scaling their products. Our goal is to provide these companies with the […]
- [o2h group announces the 5th o2h collaborative innovation conference 2023](https://o2h.com/events/the-5th-o2h-collaborative-innovation-conference/): o2h group is delighted to announce that we are back with the 5th Edition of the o2h Collaborative Innovation Conference! o2h group believes that innovationis the force that powers new industries, economies, and the way we live. The model of innovation locked inside the walls of an empire has run its course. Is one part of the answer that we ourselves create that community? We enjoy working together with others and not trying to do it alone, not least because we believe it’s the cross-fertilization of ideas across boundaries that can spur exciting new innovations. This year too, we are coming […]
- [o2h discovery launches the o2h kickstarter competition 2.0 to support Australian early stage biotechs’](https://o2h.com/discovery/o2h-discovery-launches-the-o2h-kickstarter-competition-2-0/): o2h discovery, a preclinical Contract Research Organization which has an integrated drug discovery platform, is pleased to announce the second edition of the o2h kickstarter competition 2.0 exclusively aimed towards supporting Australian early stage biotech companies. After the overwhelming response to the first competition, we are back with another edition to specifically support early stage Aus Biotech in their drug discovery programmes. Aus Biotech has a globally competitive biotech ecosystem which has impact significantly higher than its size compared to the overall global Biotech sector. We at o2h discovery have recognised this powerhouse of research excellence and are dedicating a […]
- [Azadyne, a biotech startup targeting autoimmune disease wins o2h discovery kickstarter competition](https://o2h.com/discovery/azadyne-wins-o2h-kickstarter-competition/): Cambridge, UK, November 2nd, 2022: o2h discovery is pleased to announce Azadyne as a winner of the o2h Kickstarter competition. Azadyne’s approach has shown striking efficacy in pre-clinical studies via the tRNA guanine transglycosylase (TGT) enzyme pathway against a range of autoimmune diseases without interfering with the body’s immune system.  As part of the kickstarter programme, o2h discovery will be providing small molecule synthetic chemistry to deliver improved medicines for patients with autoimmune disease, including Multiple Sclerosis. Jason Rutt, CEO said: “We are very excited and appreciative of the o2h discovery kickstarter programme. Having had some prior experience of both […]
- [o2h group is supporting upcoming Biotech Bikers' event Nov 2022](https://o2h.com/events/o2h-group-is-supporting-the-upcoming-biotech-bikers-event-2022/): We at o2h have always enjoyed organizing and participating in biotech networking rides, therefore we are once again coming up with BiotechBikers’ networking cycle ride event in Cambridge, UK. The event is scheduled on Saturday 05th November 2022 at 08:30 AM starting from Mill Scitech Park, Hauxton, Cambridge where o2h group is building a community of creators, entrepreneurs, scientists, techies, dreamers and developing an ecosystem to catalyze innovations. BiotechBikers is a global community that brings together biopharma, biotech, academic bioscience and healthcare professionals who share a passion for cycling. Mark Farmery, a biotech business developer and keen roadie based in […]
- [Kuano Limited, a quantum simulation led biotech company wins o2h discovery kick-starter competition](https://o2h.com/discovery/kuano-limited-wins-o2h-kickstarter-competition/): Cambridge, UK, Oct 03 2022: o2h Discovery is pleased to announce Kuano as a winner of the o2h Kickstarter competition. Kuano has developed a quantum simulation platform to calculate the structure of proteins during their transition state in order to design new drugs.   As part of the kickstarter programme, o2h Discovery will be providing small molecule synthetic chemistry support to their oncology focused research programmes. o2h Discovery more broadly will also support assay development, screening and ADME.  Kuano is focusing on developing enzyme inhibitors using artificial intelligence and quantum simulations to build a pipeline of oncology programmes. Kuano has designed and […]
- [o2h discovery is exhibiting at the XXVII EFMC ISMC International Symposium on Medicinal Chemistry](https://o2h.com/events/o2hdiscovery-is-exhibiting-at-the-efmc-ismc-international-symposium/): We are pleased to share that o2h discovery will be exhibiting at the XXVII EFMC International Symposium on Medicinal Chemistry held on 4-8 September at Nice, France. The XXVll EFMC-ISMC is organized by the Société de Chimie Thérapeutique (SCT), on behalf of the European Federation for Medicinal Chemistry and Chemical Biology (EFMC) which is regularly attended by scientists including chemists, biophysicists, structural biologists among others. This year EFMC-ISMC will focus on advancements in drug development in significant therapeutic areas such as bacterial and viral infections, with a focus on current and emerging viral pandemics, but also neurodegenerative and cardiovascular diseases, […]
- [o2h group is supporting the upcoming Biotech Bikers' event 2022](https://o2h.com/events/biotechbikers-millscitechpark-aug-2022/):   Networking rides have always been compelling and fun to host for us at o2h, yet we are back, again, supporting BiotechBikers’ networking cycle ride event at the same place in Cambridge, UK for all the biotech and cycling enthusiasts. The event is scheduled on Saturday 20th August 2022 at 08:30 AM starting from Mill Scitech Park, Hauxton, Cambridge where o2h group is building a community of creators, entrepreneurs, scientists, techies, dreamers and developing an ecosystem to catalyze innovations. BiotechBikers is a global community that brings together biopharma, biotech, academic bioscience and healthcare professionals who share a passion for cycling. […]
- [o2h discovery launches the o2h kickstarter competition to support early stage biotechs’](https://o2h.com/discovery/kickstarter-competition-launch/): We are excited to launch the o2h kickstarter competition exclusively for early stage biotech to boost their drug discovery research. The programme aims to extend o2h discovery’s small molecule and medicinal chemistry research expertise to seed early stage biotech companies who have innovative ideas in drug science and are planning to push it forward to the next milestones.  We understand that drug discovery research is a complex phenomenon. The first phase itself requires synthesis and screening of large numbers of new molecules to identify a “hit”. This initial phase we believe could be extremely time consuming as well as costly. […]
- [o2h discovery is sponsoring and exhibiting at the 3rd Molecules Medicinal Chemistry Symposium - 2022](https://o2h.com/events/sponsoring-and-exhibiting-at-the-3rd-mmcs-2022/): We are pleased to share that we will be sponsoring and exhibiting at the 3rd Molecules Medicinal Chemistry Symposium held on 27th-29th July 2022, in Rome, Italy.          Reach out to Claudio Dagostin if you are around! The 3rd Molecules Medicinal Chemistry Symposium (MMCS2022) is a follow-up to the successful 2nd Molecules Medicinal Chemistry Symposium—Facing Novel Challenges in Drug Discovery (MMCS2019), held in May 2019 in Barcelona, Spain, which is regularly attended by scientists including chemists, biophysicists, structural biologists among others. The aim of this event is to focus on Shaping medicinal chemistry for the new decade […]
- [o2h group is supporting the BiotechBikers' event 2022](https://o2h.com/events/biotechbikers-millscitechpark-2022/):   We are excited to be supporting the upcoming BiotechBikers’ networking event cycle ride once again in Cambridge, UK. The event will take place on Sunday 3rd July starting 8:15 am from the Mill SciTech Park where the o2h Group are shaping one of the region’s most exciting community of entrepreneurs in life science and technology. BiotechBikers is a global community that brings together biopharma, biotech, academic bioscience and healthcare professionals who share a passion for cycling. Mark Farmery, a biotech business developer and keen roadie based in Sweden, founded BiotechBikers in 2017 with the aim to bring together “bike-minded” […]
- [o2h co-work Lab Launches World’s First Influencer Tech Bootcamp](https://o2h.com/press-release/o2h-co-work-lab-launches-worlds-first-influencer-tech-bootcamp/): o2h co-work labs, a business unit of o2h group, are absolutely delighted to launch the first-ever influencer tech bootcamp covering representatives from the quintet influencer community that are the creative forces driving tech. The event is going to be held at the newly renovated Hauxton House at the Mill SciTech Park, where o2h co-work labs are building a community of creators covering life science and technology. o2h technology is a division of o2h group and partners with seed stage and growth companies to support their digital transformation journey through all phases of software development services including planning, design, development, and […]
- [Stingray Bio and o2h discovery initiate a collaboration to develop the next-generation of oncology therapeutics for cancer patients](https://o2h.com/discovery/stingray-bio-and-o2h-discovery-collaborate-for-oncology-therapeutics/): Cambridge, UK, May 04 2022: o2h Discovery is pleased to announce an integrated drug discovery collaboration with Stingray Bio, a biotechnology company headquartered in Sussex UK, to support their new oncology drug discovery programmes. Stingray Bio is developing novel small molecule cancer therapeutics targeting the LMTK3 kinase signaling pathway. The LMTK3 kinase pathway has been extensively validated as an essential component of cancer survival and growth in breast and other common cancer types. Stingray’s novel LMTK3 inhibitor drugs are designed to address diverse unmet needs in clinical cancer care. o2h Discovery will offer its drug discovery platform and assist Stingray […]
- [o2h group acquires 40,000 sq ft Hauxton Meadows site in Cambridge, UK with plans to develop state-of-the-art co-working lab spaces](https://o2h.com/press-release/acquires-40000-sq-ft-hauxton-meadows-site-in-cambridge/): Cambridge, UK, 3 May 2022: We are pleased to announce that o2h co-work labs has acquired the 40,000 sq ft Hauxton Meadows land in Cambridge, UK with plans to develop state-of-the art coworking lab spaces for life scientists and biotech entrepreneurs in the region. The Hauxton Meadows land was previously part of the Bayer crop sciences development.  The site is located adjacent to the recently developed Mill SciTech Park where the o2h co-work labs is creating one of the region’s most exciting communities of entrepreneurs in life science and technology. The new science park will have boutique lab spaces specifically […]
- [Claudio Dagostin will be representing o2h discovery at the 33rd Medicinal Chemistry Meeting](https://o2h.com/discovery/attending-the-33rd-medicinal-chemistry-meeting/): We are pleased to share that we will be attending the 33rd Medicinal Chemistry meeting by the Royal Society of Chemistry on 28th April, 2022 at Hatfield, United Kingdom. The 33rd Medicinal Chemistry meeting will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemist. This meeting is regularly attended by scientists including chemists, biophysicists, structural biologists, research scholars, etc., with the aim to discuss the latest tools & processes in […]
- [Prashant Shah, CEO of o2h co work labs and Co-Founder of o2h group shortlisted in the Cambridge Independent Awards](https://o2h.com/co-work/prashant-shah-finalists-cambridge-independent-awards-2022/): Delighted to see Prashant Shah, CEO @ o2h co-work labs and co-founder @ o2h group has been shortlisted for the CEO of the Year at the 2021-2022 Cambridge Independent #Science and #Technology Awards. From start-ups to established big hitters, the shortlist showcases once again the remarkable talent in the Cambridge region. Well done Paul Brackley and team for the great efforts they have been putting since the last five years in organising such a remarkable event. Congratulations to all our fellow finalists and looking forward to the awards ceremony in May. The Cambridge Independent awards is the premier event for […]
- [o2h discovery is exhibiting at the 8th RSC-BMCS Fragment-based Drug Discovery Meeting - 2022](https://o2h.com/events/exhibiting-at-the-rsc-bmcs-2022-conference/): We are pleased to share that we will be exhibiting at the upcoming 8th RSC-BMCS Fragment-based Drug Discovery Meeting which is held on 27th-29th March, 2022, at The Churchill College, Cambridge, UK. Reach out to Claudio Dagostin if you are around! The aim of the 8th RSC-BMCS Fragment-based Drug Discovery meeting is regularly attended by scientists including chemists, biophysicists, structural biologists, etc., with the aim to focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes.  o2h discovery is a Contract Research Organisation which has an integrated drug discovery […]
- [o2h group is attending BIA Gala Dinner 2022](https://o2h.com/events/bia-gala-dinner-2022/):  We are pleased to share that we will be attending the upcoming BioIndustry Association Gala Dinner which is held on 27th Jan 2022 at The Brewery, London. Reach out to Claudio Dagostin if you are around! The BIA Gala Dinner is regularly attended by representatives of biotech companies, investors, the government, the media, and continues to be the premier bioscience networking event providing excellent opportunities to meet with valued existing clients and network with prospective customers. For more details, visit – https://lnkd.in/dwFQ_q5z Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Data sharing made easy with Chemistry in the Cloud (CITC)](https://o2h.com/discovery/data-sharing-made-easy-with-chemistry-in-the-cloud/): We are keen to learn your feedback on using the o2h Discovery platform Chemistry In The Cloud (CITCTM). But first, Sebastien, please tell us about your background and a bit about Cedilla Therapeutics. I joined Cedilla Therapeutics 4 months ago to lead the DMPK group. I have been working in DMPK for 15 years and partnered with many different international CROs to perform our work. o2h Discovery is the first CRO (Contract Research Organization) we have partnered with based in India. We used to do all our ADME assays with Chinese CROs. Cedilla Therapeutics is a close-knit, driven, and patient-focused team […]
- [o2h Ventures is hosting Jingle Chai - A Fireside Chat with Sir Mene Pangalos](https://o2h.com/ventures/fireside-chat-with-sir-mene-pangalos/):   As the Christmas season fast approaches us, o2h Ventures is back with a Christmas special ChaiTime; ‘Jingle Chai’ this Thursday 16th December at 6.15 pm GMT (1.15 pm EST/11.45 pm IST). Adding to our series of ChaiTime webinars, we are pleased to announce that we have organized a Fireside chat with our special guest Sir Mene Pangalos. We are honored that Sir Mene Pangalos, Executive Vice-President, BioPharmaceuticals R&D Astrazeneca will join us for this Christmas special ‘Jingle Chai’ where we will gain some insights in the AZ vaccine development, research areas of focus and the role that AZ is […]
- [ImmuNext and o2h discovery collaborate to progress first-in-class drug discovery programs](https://o2h.com/discovery/collaborating-for-first-in-class-drug-discovery/): o2h discovery is pleased to announce a productive multi FTE chemistry collaboration with ImmuNext to support their cutting-edge drug discovery program focused on developing new Antibody Drug Conjugates. ImmuNext is developing immune-based therapies to treat patients with immune-related disorders, including inflammatory disease, autoimmune disorders, cancer, transplantation rejection, and infectious disease. They target critical immunomodulatory molecules that either promote or suppress immune responses to restore immune homeostasis and cure disease.  o2h discovery is delighted to provide synthetic chemistry support to help ImmuNext create new linker-payloads to deliver their groundbreaking ADCs to patients.  Jay Rothstein, CSO of ImmuNext said: “o2h has helped […]
- [o2h co work labs Hosted the World's First Influencer Biotech Bootcamp...](https://o2h.com/co-work-labs/influencer-biotech-bootcamp/): o2h co-work labs had a great time hosting the world’s first ‘influencer’ biotech bootcamp. The idea was to bring together a ‘biotech dirty dozen’, who were proven in getting their hands dirty helping British biotech flourish. We tried to nurture a vibe that was an intimate space for exchange and not a typically rigid classroom/panel/conference format. We hoped that the biotech dirty dozen would tackle subjects with their hard grass roots experiences, disagree and stir up a little controversy!  We endeavoured to bring together a mix of voices from the quintet covering (1) Scientists & Techies, (2) Biotech CXO’s, (3) […]
- [o2h discovery is exhibiting at the ElRIG UK’s annual conference Drug Discovery 2021](https://o2h.com/events/o2h-discovery-exhibiting-at-drug-discovery-2021/): Delighted to announce that o2h discovery will be exhibiting at the ElRIG UK’s annual conference Drug Discovery 2021 on 19th – 20th Oct.  2020 was a year of challenge, but it was also a turning point for our industry, as our community came together and was at the forefront of the scientific effort to overcome and manage the COVID virus.  Together we made unprecedented scientific progress, which we will recognize and celebrate at Drug Discovery 2021. ELRIG’s annual Drug Discovery meeting is still Europe’s largest meeting for life sciences industry professionals and will return in the autumn of 2021, to […]
- [o2h Ventures “Human Health SEIS Fund” Invests into Sanome...](https://o2h.com/ventures/human-health-seis-fund-invests-into-sanome/): Cambridge, UK, 28 Sept 2021: o2h Ventures is pleased to announce an investment into Sanome, a London-based biotech company combining biomarkers (health data points) into a human health passport that helps people understand and manage their health better. Sanome raised £2m as its first round of funding from a number of leading UK and European HealthTech specialist investors including o2h Ventures. Sanome is a digital health company that has developed a diagnostics innovation engine that combines biomarkers to produce medical-grade, at-home diagnostic products (IVDs) more efficiently and effectively. Most digital health, wearables, and consumer biotech tools have limited medical use […]
- [o2h co-work Labs Launches the World’s First Influencer Biotech Bootcamp...](https://o2h.com/co-work-labs/worlds-first-influencer-biotech-bootcamp/): Cambridge, UK, 23 Sept 2021: o2h co-work labs, a business unit of o2h Group, are absolutely delighted to launch the first ever influencer biotech bootcamp covering representatives from the quintet influencer community that are the creative forces driving biotech. The event is going to be held at the newly renovated the old Mill house at the Mill SciTech Park, where o2h co-work labs is building a community of creators covering life-science, technology and green innovation. Looking far beyond the ‘start-up’ skills the bootcamp endeavours to bring together a dozen influencers covering the quintet of (1) Scientists & Techies (2) Biotech […]
- [o2h group is supporting the upcoming BiotechBikers' networking event in The UK](https://o2h.com/events/supporting-biotechbikers-networking-event-uk/):     We are excited to be supporting the upcoming BiotechBikers’ networking event cycle ride in Cambridge, UK. BiotechBikers brings together “bike-minded” pharma professionals in a unique networking community based around guided group rides, virtual meetups and other social events. The event will take place on Saturday 18th September starting 8:15 am from the Mill SciTech Park where the o2h Group are shaping one of the region’s most exciting community of entrepreneurs in life-science, technology and green innovation. Find the Event agenda below : 08:15 – 09:00 Pre-ride refreshments and networking 09:00 – 12:15 Two social rides, a short and steady […]
- [o2h Ventures makes it to the finals in the EISA Awards 2021...](https://o2h.com/ventures/makes-it-to-the-finals-eisa-awards-2021/): Delighted to share that o2h Ventures has been shortlisted as a finalist in the upcoming EISA Awards 2021 in the Best Newcomer category. The 2021 EISA Awards denote excellence in a number of EIS/SEIS fields and recognise the achievements of EIS/SEIS practitioners during the past year. The awards have a stellar judging panel again this year with a wide variety of experience from across the EIS and small business industry who independently assess entries and determine winners based on merit alone. o2h Ventures is the fund manager of the o2h Human Health Knowledge-Intensive EIS Fund which is the first HMRC […]
- [o2h Ventures backed In4Derm enters into an exclusive license agreement with VYNE Therapeutics](https://o2h.com/team-ventures/in4derm-enters-in-an-exclusive-agreement/):   VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in 2022 BRIDGEWATER, N.J., August 12, 2021 — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has entered into an exclusive license agreement (the “License Agreement”) with In4Derm Limited (“In4Derm”), a spin-out of the University of Dundee’s School […]
- [o2h Ventures ‘Knowledge Intensive Human Health EIS Fund’ invests into BiVictriX Therapeutics](https://o2h.com/ventures/o2h-ventures-knowledge-intensive-human-health-eis-fund-invests-into-bivictrix-therapeutics/): Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.  BiVictriX is dedicated to applying a novel approach in developing safer and effective cancer therapies, by revolutionizing cancer therapy and making curative treatments available to all; By delivering a broad pipeline of proprietary, first-in-class Bi-Cygni® therapeutics to enable potentially higher dosing and more aggressive tumor eradication in patients, without causing harmful side effects. The company also announced that it will be listed on the AIM […]
- [Digital brain biomarker company Monument Therapeutics raises £2.6 million](https://o2h.com/press-release/digital-brain-biomarker-company-monument-therapeutics-raises-2-6-million/): Manchester, UK, June 28, 2021: Monument Therapeutics, a stratified medicine company, today announced it has raised £2.625 million in seed funding to spin out of Cambridge Cognition Ltd and relocate to Alderley Park, Cheshire. The new company will focus on applying digital biomarkers to neuroscience drug development with a view to matching patient sub-groups with appropriately targeted compounds. Monument Therapeutics applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  Monument Therapeutics has a pipeline of promising drug development programmes, with the most advanced two being for cognitive impairment in schizophrenia and […]
- [Neophore closed £15.2m series B round successfully and expands its drug discovery collaboration with o2h discovery](https://o2h.com/press-release/neophore-closed-series-b-round-successfully-and-expands-its-drug-discovery-collaboration-with-o2h-discovery/): Cambridge, UK, July 05 2021: o2h discovery is delighted to announce that one of its collaborators, NeoPhore Limited, a small molecule neoantigen immuno-oncology company has closed a successful £15.2m (US $21m) Series B round and has also expanded its drug discovery collaboration with o2h discovery. NeoPhore Limited is dedicated to developing novel small molecules to treat cancer through stimulation of the immune system. NeoPhore’s drug target’s genetic mechanisms will promote neoantigen creation and diversity across numerous cancers.  o2h discovery is committed to provide synthesis chemistry support to NeoPhore Limited to help them deliver on their groundbreaking science through the next […]
- [o2h Technology appoints serial entrepreneur Fiona Nielsen as Chief Operations Officer](https://o2h.com/press-release/o2h-technology-appoints-fiona-nielsen-as-chief-operations-officer/): Cambridge, UK, July 1 2021: o2h Technology, the software services business unit of the o2h group, today announced it has appointed Fiona Nielsen as Chief Operations Officer, in line with recent business growth and increasing customer demand. Fiona Nielsen brings 20 years of experience in the Technology and life science industry. With a background in computer science combined with her degree in Bioinformatics Fiona arrived in Cambridge, UK, to work for deep-tech life science company Illumina before emerging as an entrepreneur in genomics and life science. In her latest venture Repositive Fiona built a data organisation and inventory management platform […]
- [o2h group is observing Kindness Day in memory of Shabu Thomas](https://o2h.com/events/second-kindness-day/): Shabu Thomas also known as the Chief Heart Officer will always be an integral part of the o2h family as he lives forever in the o2h group through his values and memories.  He joined the o2h group in 2005 and led the HR function until 2013 and then returned in 2016 to lead the operations until his sad passing away two years ago. Shabu was a gem of a man and one of the most gentle, compassionate, and good-humored people any of us have ever met. Therefore, in memory of Shabu and to honor him, the o2h group is observing […]
- [o2h Ventures backed In4Derm Announces a Strategic Partnership with a Nasdaq listed biotech with a >$200 Option License Agreement](https://o2h.com/press-release/o2h-ventures-backed-in4derm-signed-an-option-and-licensing-agreement/): Cambridge, UK, May 2021: o2h Ventures are excited to announce that In4Derm, backed by the fund managers “o2h human health EIS fund” has signed an Option and Licensing Agreement based around its pipeline of first-in-class, selective BET inhibitors. The strategic partnership brings further financial and development support to In4Derm in addition to a novel pipeline for the partner. Sunil Shah, CEO at o2h Ventures said: “This early discovery stage collaboration will both provide the resources and speed up the time to provide novel drug therapeutics to patients. The first commercial deal for the company is a great platform for the […]
- [Sunil Shah, CEO of o2h ventures, wins the Cambridge Independent Science and Technology Awards as CEO of the Year](https://o2h.com/press-release/sunil-shah-wins-the-cambridge-independent-awards-as-ceo-of-the-year/): Cambridge, UK, 16th April 2021 We are delighted to announce that Sunil Shah of o2h ventures has won the prestigious award at the Cambridge Independent Science and Technology Awards as CEO of the Year.  Sunil and his brother (co-founder) Prashant have been building the Anglo-India o2h Group together since 2003. They have built a scientifically driven ecosystem of ~350 people to support and invest into early stage therapeutic, AI driven biotech companies.  The o2h Group has research infrastructure and investments in Cambridge, UK and Ahmedabad, India with collaborations across three continents. In Cambridge UK, o2h Group has been developing the […]
- [Mill SciTech Park pre-planning application submitted](https://o2h.com/co-work/mill-scitech-park-pre-planning-application-submitted/): A pre-planning application for the development of the Mill SciTech Park, on the Hauxton Mill site in South Cambridgeshire has been submitted by o2h Group. The Cambridge-based business behind the project believes this marks an important step in the delivery of their exciting proposals which would see the creation of a state-of-the-art office and laboratory space. The ambitious project, which has been partly funded by a Local Growth Fund grant from the Cambridgeshire & Peterborough Combined Authority aims to transform the 2.76-acre heritage site at Hauxton Mill into one of the region’s most exciting communities of entrepreneurs in life sciences, […]
- [o2h group in the finals of Cambridge Independent Science and Tech Awards 2020](https://o2h.com/events/finalists-in-the-cambridge-independent-science-and-tech-awards-2020/): We are delighted to share that o2h group are one of the finalists in the Cambridge Independent Science and Tech Awards 2020. The awards which are in their fourth year celebrate the Cambridge region’s extraordinary talent and have grown dramatically since their inception. Following hundreds of entries, a shortlist across 14 categories were drawn up which represents an array of great talent – emerging and established – from across the Cambridge region in all the fields from biotech, medtech to AI. AI Chemistry in the CloudTM, the world’s first scientific project management app built by o2h technology was shortlisted for […]
- [Press Release – o2h group accomplished its goal of planting ten thousand trees](https://o2h.com/community/o2h-group-planted-ten-thousand-trees/): Ahmedabad, India, 23rd Nov 2020: We are pleased to share that the o2h group has accomplished its goal of planting ten thousand trees across various regions of Gujarat in collaboration with VSSM and The Ahmedabad Project. The o2h group has embarked on a ambitious journey of becoming a carbon neutral company in near future. This was communicated to the world by Nilesh Dagia, COO, o2h discovery at the 2019 International Institute for Sustainable Laboratories Annual Conference (I2SL); where he also won the I2SL Go Beyond Award for demonstrating a commitment to advancing both science and sustainability in laboratories. As a […]
- [o2h ventures launches the first HMRC approved knowledge intensive EIS fund focused on UK biotech therapeutics & AI](https://o2h.com/press-release/knowledge-intensive-eis-fund-launch/): o2h ventures is delighted to announce the launch of their HMRC approved knowledge intensive EIS fund, focusing on supporting the expansion of UK research and development in biotech therapeutics and AI. To support the Government’s aim to strengthen and grow UK innovation, which were known to be capital and research intensive, the EIS knowledge intensive fund has been launched to pledge support to companies working in this space, providing them access to capital to develop their early novel ideas. Knowledge intensive investing offers investors an opportunity to take advantage of the predictability of the tax year, from which they are […]
- [o2h discovery is exhibiting at the 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry symposium](https://o2h.com/events/o2h-discovery-exhibiting-3rd-rsc-ai-chemistry-symposium/): Delighted to announce that o2h discovery will be exhibiting at the 3rd RSC-BMCS / RSC-CICAG Artificial Intelligence in Chemistry symposium. Following the successes of two “Artificial Intelligence in Chemistry” meetings in 2018 and 2019 the third symposium is organised by the RSC BMCS (Biological and Medicinal Chemistry Sector) and the RSC CICAG (Chemical Information and Computer Applications Group). The two day symposium will take place virtually on 28th – 29th of September 2020 and will combine aspects of artificial intelligence and deep machine learning methods to applications in chemistry. Sunil Shah, Tejas Upadhyay and Andy Morley will be representing o2h […]
- [o2h group announces Kindness Day in memory of Shabu Thomas](https://o2h.com/events/o2h-group-kindness-day/): Shabu Thomas also known as the Chief Heart Officer will always be an integral part of the o2h family as he lives forever in the o2h group through his values and memories. Shabu was a gem of a man and one of the most gentle, compassionate, and good-humored people any of us have ever met. Therefore, in memory of Shabu and to honor him, the o2h group is observing Kindness Day on 26th June 2020. We have planned several activities such as prayers and sharing of memories by close colleague. We are also encouraging each member of the o2h family […]
- [o2h community collaborated with The Ahmedabad Project to plant over 2000 trees](https://o2h.com/community/o2h-community-the-ahmedabad-project-tree-plantation/): Earlier this year, the o2h community collaborated with The Ahmedabad Project to plant over 2000 trees in the community managed urban forest at Thaltej, Ahmedabad. The Ahmedabad Project was founded by Renu Pokhrana and aims to create awareness on governance among the citizens. This collaboration was in line with o2h group’s aim of becoming a carbon neutral company in the near future and planting 10,000 trees as a first step – besides other sustainable development practices adopted and implemented internally across all the sites. An urban forest, as the name suggests, is a systematic method of developing mini forest or […]
- [Fighting Coronavirus - an update on Remdesivir by Gilead](https://o2h.com/therapeutics/fighting-coronavirus-an-update-on-remdesivir-by-gilead/): Great to see the recent early clinical trial results for Remdesivir showing some benefit in a small study of hospitalised infected patients.(1) The results of larger more detailed trials will be eagerly awaited. If effective the need to supply significant amounts of this drug will be essential. The synthesis of Remdesivir is a long linear process, although the cost per dose is relatively cheap. Gilead have made significant improvements to the manufacturing route, reducing it from one year to six months.(2) If Remdesivir is shown to be effective in larger trials, the demand for the drug will significantly outstrip the ability […]
- [Impacting COVID-19 – Opportunities for Chemists](https://o2h.com/therapeutics/impacting-covid19-opportunities-for-chemists/): Dear Chemists, We’re all aware of the situation we all are currently facing. We do these jobs for a love of chemistry and to steal a punchline from my old employer, making a meaningful difference to patients humanity. Now is the time when we can openly collaborate to do our part and potentially protect many lives. Gilead’s Remdesivir looks to be the most promising compound to help tackle COVID-19 in the short/medium term, along with a number of molecules that are in clinical development or repurposing of marketed drugs (including hydroxychloroquine, camostat etc., to name a few). If any of […]
- [Delighted to Announce the 3rd o2h group collaborative innovation conference](https://o2h.com/o2h-events-and-conferences/3rd-o2h-collaborative-innovation-conference/): Register Now! Download Brochure Watch Live on YouTube Innovation is the force that powers new industries, economies and the way we live. The model of innovation locked inside the walls of a big company is struggling. Is one part of the answer a model where we ourselves create a community of collaborative innovators? At o2h group, we enjoy working together with others and not trying to go it alone not least because it’s the cross fertilisation of ideas across boundaries that can spur exciting new innovations. We are passionate about playing our part in the creation of a collaborative community […]
- [o2h community has completed the first stage of its campaign to plant 10,000 trees](https://o2h.com/community/completed-the-first-stage-of-its-tree-plantation-campaign/): We are pleased to share that o2h community has completed the first stage of its campaign to plant 10,000 trees. The announcement was made in Oct 2019 by Nilesh Dagia, COO, o2h discovery after he received the I2SL- International Institute of Sustainable Labs award for leading the design and execution of the upcoming Shirish Research Park for o2h discovery. We have collaborated with Vicharta Samuday Samarthan Manch (VSSM), an NGO based out of Ahmedabad which rehabilitates water-starved regions of India. Mittal Patel, the founder of VSSM was recently honoured by the President of India for her contribution to empowering the […]
- [o2h ventures portfolio company Exonate announces collaboration with Johnson & Johnson](https://o2h.com/o2h-ventures/exonate-announces-collaboration-with-johnson-and-johnson/): o2h Ventures portfolio company Exonate Announces a Collaboration with Janssen to develop a new eye drop for the treatment of retinal vascular diseases, including wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO) The program, facilitated by Johnson & Johnson Innovation, has the potential to improve the treatment of patients with retinal vascular diseases and transform the lives of those suffering from vision loss. Cambridge, UK, 13 January, 2020: Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. […]
- [Nilesh Dagia, COO, o2h discovery, wins the International Institute for Sustainable Labs (I2SL) Go Beyond Award](https://o2h.com/discovery/nilesh-dagia-coo-o2h-discovery-wins-the-go-beyond-award/): Colorado, USA, November 13 2019: We are absolutely delighted to announce that Nilesh Dagia, COO, o2h discovery, has won the Go Beyond Award in the Individual category at the 2019 I2SL Annual Conference. The Go Beyond award goes to the individual that demonstrated a commitment to advancing both science and sustainability, and their efforts to contribute to the overall goal of more efficient laboratories across the world. Nilesh won the award for leading the design and execution of energy-efficient and environmentally responsible labs for o2h discovery in India. The Go Beyond Awards is a unique awards program honoring organizations, individuals, […]
- [Sunil Shah, CEO, o2h discovery Wins Special Recognition Award by OBN UK Ltd](https://o2h.com/discovery/sunil-shah-ceo-o2h-discovery-wins-special-recognition-award-by-obn-uk-ltd/): We are absolutely delighted to announce that Sunil Shah, CEO, o2h discovery, has won the Special Recognition Award at the industry leading OBN Awards 2019 event organised by OBN (UK) Ltd, the membership organisation that supports the life sciences industry.  The Awards, which are in their 11th year, celebrate the best of UK life sciences – from outstanding scientific innovation within Biotech, Medtech and Digital Health, to the companies that support the industry and the fundraisers that make it happen.  Sunil Shah won the award for “his rare vision and supportive ethos to the companies he invests in: offering support […]
- [o2h discovery expands synthetic chemistry collaboration with Sosei Heptares](https://o2h.com/discovery/o2h-discovery-expands-synthetic-chemistry-collaboration-with-sosei-heptares/): Cambridge, UK, October 22 2019: o2h discovery is pleased to announce a significant expansion in its existing Synthetic Chemistry collaboration with Sosei Heptares, an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. o2h discovery supports biotechnology and pharmaceutical companies with drug discovery support from its research facility in Ahmedabad, India and is developing additional discovery biology capabilities from The Mill SciTech Park in Cambridge, UK which the o2h group recently acquired. John Christopher, Director of Medicinal Chemistry at Sosei Heptares noted that: “Sosei […]
- [o2h ventures makes it to the finals in the Tax Efficiency Awards](https://o2h.com/o2h-ventures/o2h-ventures-finalist-tax-efficiency-awards-investmentweek/): Delighted to announce that the o2h ventures is a finalist for ‘The Best New Entrant’ in the 2019/20 Tax Efficiency Awards by Investment Week. The awards are designed to recognise the most successful and forward-thinking providers in the areas of VCTs, EIS and BPR/IHT. Stay tuned to see if we win the award! To read the full list of finalists, please see: https://bit.ly/338I23oPress Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Pleased to Announce the 13th Edition of o2h Women's Open Day](https://o2h.com/community/pleased-to-announce-the-13th-edition-of-o2h-womens-open-day/): We are absolutely delighted to welcome you and the young talented graduates from all walks of life, to the 13th edition of o2h Women’s Open Day. We will share with you exciting journeys of women who have overcome personal challenges, from family and society, and have excelled in the field of science, technology, academia, social enterprise, architecture, and many more such fields.
- [Cedilla Therapeutics and o2h discovery are pleased to announce multi FTE expansion to their synthetic chemistry collaboration](https://o2h.com/discovery/o2h-discovery-pleased-to-announce-multi-fte-expansion-with-cedilla-therapeutics/): Cambridge, UK/MA, September 11 2019: o2h discovery is pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock Ventures backed biotech company based in the Cambridge, MA. Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.  o2h discovery is pleased to collaborate with Cedilla, to support their aim of charting new paths to target proteins that have long been outside the reach of drug […]
- [Chemistry Process Optimization – an inevitable parameter for the developmental phase of the drug discovery process](https://o2h.com/discovery/chemistry-process-optimization/): The cycle of a molecule from merely a structure on paper to a proven drug sold in the market is technically divided into 3 different Phases which can be further classified under – Discovery (Research), Development (Process Optimization) & Commercialization (Sales and Marketing). The first of these three criteria which is “Research” – consumes the highest amount of time in the entire drug life cycle, and is very tedious. As we all know, for “Research” establishing the “Proof of Concept” is most important because until this is done everything else is in vain. Therefore, while doing R&D saving time over […]
- [o2h ventures Makes an Investment in Small Pharma](https://o2h.com/ventures/o2h-ventures-makes-investment-in-small-pharma/): Funding to enable further investigate an oral antidepressant based on a metabolite of ketamine and a 5HT2A agonist for treatment resistant depression. Identify collaborative opportunities with Pharma or larger biotech with assets in which they can deploy the specialist patent expertise developed. Cambridge, UK, 17th July 2019: The o2h therapeutics and AI Fund (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutics and related AI opportunities, is pleased to announce an investment in Small Pharma. The leadership team have experience in both drug development process and IP, and have looked at difficult to patent treatments for depression. The […]
- [Q&A with Angel Investor Sunil Shah | The Sunday Times](https://o2h.com/o2h-ventures/o2h-ventures-sunil-shah-the-sunday-times/):   Sunil Shah, CEO of o2h ventures who recently won The Angel Investor of the Year by UKBAA was interviewed by Peter Evans, Enterprise Editor of The Sunday Times.  The Q&A session was themed around Biotech Investing in the UK in which Sunil Shah has played an instrumental role since many years both as an active angel investor and a mentor. He shared his experience and future thoughts on the potential of Biotech and AI in the UK in the light of the recently launched o2h therapeutics and AI EIS fund. To read the full article, please click here- Q&A […]
- [Sunil Shah, o2h ventures wins Angel Investor of the Year](https://o2h.com/o2h-ventures/sunil-shah-o2h-ventures-wins-angel-investor-of-the-year/): Cambridge, UK, 4th July 2019. We are delighted to announce Sunil Shah, CEO, o2h ventures, has won the prestigious UKBAA Angel Investor of the Year Award for his active participation in backing high growth potential startups and early-stage businesses in the UK. Sunil’s contribution has been instrumental in the growth of biotech in UK. He has been investing into the biotech therapeutics sector since many years – a sector from which traditionally many angel investors have stayed away. Over the years, Sunil has championed EIS Angel investing and biotech therapeutics to generate investment into companies. He has also added immense […]
- [Sunil Shah, CEO, o2h ventures, makes it to final in the UKBAA Awards 2019](https://o2h.com/o2h-ventures/sunil-shah-ceo-o2h-ventures-makes-it-to-final-in-the-ukbaa-awards-2019/): We are delighted to announce that Sunil Shah, CEO, o2h ventures, has been shortlisted for Angel Investor of the Year at the UKBAA Angel Investment Awards 2019! This Award recognises the most active and impactful angel investor in backing start-up and early stage UK businesses during the past 12 months and who has brought not only vital risk capital, but also significant added value to support the growth and success of their portfolio. The awards will be held at Illuminate at the Science Museum in London on Tuesday 2nd July, 2019. This fantastic event will recognise the fastest growing brands […]
- [Oxford Drug Design recieves over £8m in grant and equity investment](https://o2h.com/ventures/oxford-drug-design-recieves-over-8m-in-grant-and-equity-investment/): Oxford Drug Design (ODD) wins major funding awards from CARB-X, the UK Department of Health and Social Care (DHSC) and an equity investment led by o2h Ventures totaling over £8m to develop new antibiotics effective against drug-resistant superbugs and to expand its proprietary machine learning computational platform. Oxford, UK, 18th June 2019– Oxford Drug Design Limited, a biotechnology company with a proprietary computational and machine learning platform, announced today that CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) has agreed to back their lead in-house discovery project with a milestone dependent, non-dilutive, award for over £5M. In parallel, the project will be further […]
- [Privitar Raises $40 Million Series B Funding Round Led by Accel to Facilitate the Safe and Ethical Use of Data](https://o2h.com/o2h-ventures/privitar-raises-40-million-series-b-funding-round/): LONDON & BOSTON, June 10 2019 — Privitar, the data privacy software company, announced it has closed a $40 million Series B funding round led by global venture capital firm Accel, with participation from existing investors Partech, Salesforce Ventures, 24Haymarket and IQ Capital. The investment strengthens the company’s leadership position in the global data privacy market. Seth Pierrepont, Partner at Accel, will join Privitar’s board of directors. Data privacy is now top of mind. Following high-profile events like the Equifax breach and the Cambridge Analytica scandal, consumers around the world are increasingly concerned with how enterprises are handling their personal […]
- [o2h Ventures makes it to the final in the Great EIS 25th Year Anniversary Awards](https://o2h.com/o2h-ventures/o2h-ventures-finalist-in-the-great-eis-25th-year-anniversary-awards/): The Great EIS Banquet is a high-profile event run by the official group EISA to represent the EIS investing industry. This year will be a larger and higher profile event to celebrate 25 years of EIS investing, and the winner will be announced at the gala ball at The Banqueting House, Whitehall on Thursday, 20th June 2019. o2h Ventures entered the very competitive category as an outstanding impact investor. As a relatively new EIS Fund , and given the large number of entries we were hesitant to enter, however, in the last 3 months we have made 4 investments from […]
- [Metrion Biosciences Closes Funding Round- o2h Ventures](https://o2h.com/ventures/metrion-biosciences-closes-funding-round/): Cambridge, UK, 01 April 2019: Metrion Biosciences Ltd (“Metrion”), the specialist ion channel contract research and drug discovery company, announced today that it has completed a fully subscribed funding round on 14 March. Metrion will use the funds to support the broadening of its ion channel screening capabilities, and continued research into novel Kv1.3 inhibitors for the treatment of auto-immune conditions.
- [The o2h Therapeutics and AI Fund makes investment in early stage biotechnology company](https://o2h.com/o2h-therapeutics-and-ai-s-eis-fund/the-o2h-therapeutics-and-ai-fund-makes-investment-in-early-stage-biotechnology-company/): Cambridge, UK, 28 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotechnology therapeutic and related AI opportunities, is pleased to announce an investment in Exonate, an early stage biotechnology company.
- [2% off the initial fee for The o2h Therapeutics and AI S/EIS Fund](https://o2h.com/o2h-therapeutics-and-ai-s-eis-fund/2-percent-off-the-initial-fee-for-o2h-therapeutics-and-ai-eis-fund/): We are grateful to our early investors of The o2h Therapeutics and AI EIS Fund and should they wish to increase their participation in the upcoming deals we have put forward an offer for them to invest before the end of the tax year on April 5th with a 50% reduction in the initial fee from 4% to 2%. 
- [Press Release - The o2h Therapeutics Fund makes its first investment](https://o2h.com/o2h-therapeutics-and-ai-s-eis-fund/press-release-the-o2h-therapeutics-fund-makes-its-first-investment/): Cambridge, UK, 14 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotech therapeutic and related AI opportunities, has made its first investment, backing DeepMatter Group Plc (“DeepMatter”), a big data company which is at the forefront of the digitization of chemistry. DeepMatter Plc is based in Glasgow and is quoted on the Alternative Investment Market (AIM). The group has developed DigitalGlasswareTM, an artificial intelligence-enabled cloud-based software and hardware platform allowing chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. This enables chemists to work […]
- [The o2h Innovation Conference 2019 14th March at Courtyard by Marriott, Ahmedabad](https://o2h.com/events/the-o2h-innovation-conference-2019/): o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing biotech therapeutic and related AI  opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.
- [o2h ventures limited has now launched the o2h therapeutics fund](https://o2h.com/ventures/o2h-ventures-limited-has-now-launched-the-o2h-therapeutics-eis-fund/): o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing biotech therapeutic and related AI  opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.
- [Arecor secures £6M investment for the clinical development of its diabetes speciality pharma portfolio](https://o2h.com/ventures/arecor-secures-6m-investment-for-the-clinical-development-of-its-diabetes-speciality-pharma-portfolio/): Cambridge, UK., 10 September 2018: Arecor Ltd (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development of the Company’s speciality pharma portfolio of proprietary diabetes products.

## Pages

- [8th Collaborative Innovation Conference 2026](https://o2h.com/8th-collaborative-innovation-conference-2026/)
- [Welcome to o2h group](https://o2h.com/)
- [Cookies Policy](https://o2h.com/cookies-policy/): This Cookies Policy explains how o2h Group (“Company”, “We”, “Us”, or “Our”) uses cookies on our website https://o2h.com/ (the “Website”). By continuing to use our website, you consent to our use of cookies as outlined in this policy. What Are Cookies? Cookies are small text files placed on your device (computer, tablet, or mobile) when you visit a website. They help enhance functionality, improve user experience, and analyze website performance. Cookies do not typically contain personally identifiable information. However, some data stored in cookies may be linked to personal information we process. Please refer to our Privacy Policy for further […]
- [7th Collaborative Innovation Conference 2025](https://o2h.com/7th-collaborative-innovation-conference-2025/)
- [Agreement for Platinum Partnership](https://o2h.com/agreement-for-platinum-partnership/)
- [thank you kickstarter innovate america](https://o2h.com/thank-you-kickstarter-innovate-america/): Deepshikha, from our BD team, will shortly reach out to you for more details. In case of any queries, please feel free to reach out to us at kickstarter@o2h.com
- [kickstarter innovate america registration](https://o2h.com/kickstarter-innovate-america-registration/)
- [o2h Kickstarter Innovate America](https://o2h.com/o2h-kickstarter-innovate-america/)
- [o2h platinum partner registration](https://o2h.com/o2h-platinum-partner-registration/)
- [o2h discovery platinum partner](https://o2h.com/o2h-discovery-platinum-partner/)
- [Protac contact page](https://o2h.com/protact-contact-page/)
- [thank you kickstarter usa](https://o2h.com/thank-you-kickstarter-usa/): Deepshikha, from our BD team, will shortly reach out to you for more details. In case of any queries, please feel free to reach out to us at kickstarter@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [kickstarter usa registration](https://o2h.com/kickstarter-usa-registration/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [the o2h kickstarter competition usa](https://o2h.com/the-o2h-kickstarter-competition-5-0/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [event](https://o2h.com/exhibiting-attending-events/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [thank you protac toolbox™](https://o2h.com/thank-you-protac-toolbox/): Deepshikha, from our BD team, will shortly reach out to you for more details and to share the o2h PROTAC toolbox™ PDF Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [kickstarter italy registration](https://o2h.com/kickstarter-italy-registration/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [thank you for applying for o2h platinum partner](https://o2h.com/thank-you-o2h-platinum-partner/): Someone from our team will get back to you shortly and in case if you have any queries, please do not hesitate to get in touch with us at platinumpartner@o2h.com   Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [thank you for downloading kickstarter PDF](https://o2h.com/o2h-discovery-platinum-partner/thank-you-for-downloading-pdf/): In case if you have any queries, please do not hesitate to get in touch with us at platinumpartner@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h kickstarter competition](https://o2h.com/the-o2h-kickstarter-competition/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [the o2h kickstarter competition italy](https://o2h.com/the-o2h-kickstarter-competition-4-0/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [kickstarter Award golden ticket  registration](https://o2h.com/o2h-kickstarter-golden-ticket-registration/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [LNP page](https://o2h.com/lipid-nanoparticles/):               Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h kickstarter golden award](https://o2h.com/o2h-kickstarter-golden-ticket-award/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [the o2h kickstarter competition 3.0](https://o2h.com/the-o2h-kickstarter-competition-3-0/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h kickstarter competition - BII](https://o2h.com/o2h-kickstarter-competition/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Protac Services](https://o2h.com/protac-synthesis-services/):         Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [collaborative innovation conference 2024](https://o2h.com/collaborative-innovation-conference/):                                                                                                         Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Thank you](https://o2h.com/thank-you/): In case if you have any queries, please do not hesitate to get in touch with us at invest@o2h.comPress Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [download-information-memorandum](https://o2h.com/download-information-memorandum/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [thank you kickstarter](https://o2h.com/thank-you-kickstarter/): Deepshikha from our BDE team will get back to you and in case if you have any queries, please do not hesitate to get in touch with us at kickstarter@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [the o2h kickstarter competition 2.0](https://o2h.com/the-o2h-kickstarter-competition-2-0/): give your start-up a boost of chemistry…Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [kickstarter registration](https://o2h.com/kickstarter-registration/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Innovation Conference](https://o2h.com/collaborative-innovation-conference-2022/): We are delighted to announce that we are back with the 4th edition of the o2h collaborative Innovation Conference where we will endeavour to bring together an exciting community of live operators in science, technology, academia, entrepreneurship, social enterprise, investment, art, media, creative, engineering, architecture, and big business. Innovation is the force that powers new industries, economies and the way we live. The model of innovation locked inside the walls of an empire has run its course. Is one part of the answer that we ourselves create that community? At o2h group, we enjoy working together with others and not […]
- [Corporate Social Responsibility Policy](https://o2h.com/csr-policy/): policy overview: o2h group is a community aware company and has been working with various organisations on a number of programmes. We understand that we have a contribution to make to the community and society in which we do our work, not at some unspecified point in the future, but now, and as part of our life journey, however small that contribution is. o2h Group encourages contribution, partnerships and connections with NGOs and the community.  We have been active with a number of local organisations, including – HIV orphanage, old-people’s homes, organisations supporting women’s rights in disadvantaged areas of the […]
- [Co-Work-Labs](https://o2h.com/co-work-labs/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [chaitime banner content](https://o2h.com/chaitime-banner-content/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Privacy Policy](https://o2h.com/privacy-policy/): Introduction ​ At o2h Group we take your privacy seriously and we are committed to protecting Personal Data (information) that we receive from you. This Privacy Policy explains our policies and practices regarding the processing of your Personal Data and explains your privacy rights under applicable privacy and security laws. We notify you of this under the General Data Protection Regulation. ​ We review our privacy practices on an ongoing basis, so we may change this Privacy Policy from time to time. If such changes include any significant, material changes, we will provide clear notice on our website: www.o2h.com. Contacting […]
- [Thank you brochure download](https://o2h.com/thank-you-for-downloading-brochure/): In case if you have any queries, please do not hesitate to get in touch with us at info@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h Chaitime](https://o2h.com/chaitime/): o2h chatime is an exciting webinar series which covers a range of interesting topics from drug discovery therapeutics and investing, to arts and culture. The webinars feature popular panelists ranging from top scientists, prominent roles in pharmaceuticals, founders of start-ups to well known performance artists and architects. Register for invitations to our upcoming webinars and brew up your Chai!Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h discovery presentation](https://o2h.com/presentation/):  Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h discovery - Media Library](https://o2h.com/discovery/media/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [起業家科学者](https://o2h.com/jp/discovery-delivery/entrepreneurial-scientists/): o2hは各科学者を起業家と見なし、継続的な学習と自己啓発を促進する環境を提供することを目指しています。 私たちは、プロジェクトを管理し、積極的に能力を最大限に発揮する科学者を高く評価しています。彼らの役割におけるリーダーシップをさらに奨励し、世界最高のサービス会社であることに焦点を当てることを念頭に置いて、各科学者の報酬の12.5％はお客様のフィードバックに関連付けられています。プロジェクトの開始時に、プロジェクトの優先順位を入念に収集し、それぞれの科学者やチームリーダーに伝え、これらの優先順位を達成できるように支援します。 お客様との直接かつ頻繁なコミュニケーションによる積極的な問題解決は、プロジェクトの実施に影響を与える可能性のある異文化問題への感作とともに、コミュニケーションと英会話の社内トレーニングプログラムによってサポートされています。ケンブリッジを拠点とする私たちの科学連絡員は、インドと英国の両方での経験を持ち、この点に関して私たちの科学者をさらにサポートしています。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [技術のアドバンテージ](https://o2h.com/jp/discovery-delivery/skills-advantage/): o2hは学習とエンパワーメントの環境の構築に重点を置いており、各科学者が自分の仕事の全責任を負い、最適な提供に必要な資源とサポートを積極的に探すことが奨励されています。 科学者のスキルを継続的に改善し、最新の技術に遅れをとらないようにすることは、創薬の成功に不可欠です。毎月2回開催される定期的なセミナーは、科学、リーダーシップ、コミュニケーションの重要な分野で、社内の専門家や科学者からの提案で招待された講演者によって予定されています。 この文化によって、科学者の離職率は非常に低くなり、IPの安全性と社内でのスキルの保持を強化することでお客様に利益をもたらしています。また、o2hはプロセスを継続的に監視および更新し、関連性および最適化された状態を保ちます。このプロセスは、社内の科学者とお客様の両方からのフィードバックループの一環であり、お客様の優先事項が満たされ、プロジェクトの各ポイントで正しい成果物が設定されるようにします。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [全面的なサポート](https://o2h.com/jp/discovery-delivery/360-degree-support/): 創薬プロジェクトの成功は、タイムリーなトラブルシューティングと潜在的な問題の実用的な解決策の発見にかかっています。 o2hの科学者は、プロジェクトに集中する時間を最大化することを目的とした全面的なサポートシステムによって支援されます。これらのサポートシステムには、セカンドシフトの科学者、24時間年中無休の分析ラボ、オンラインの科学データベースへのアクセスが含まれます。 o2hの各プロジェクトチームには、ラボの技術者、セカンドシフトの化学者、分析化学者で構成されるサポートスタッフが割り当てられています。科学者は、購買チーム、英国のオフィスおよびプロジェクトマネージャーからもサポートを受けています。 全面サポートの重要な部分は、継続的な技術スキルの更新と、定期的な科学トレーニングプログラムと専門家による研究セミナーによる従業員の新しい技術のトレーニングです。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [分析](https://o2h.com/jp/discovery-delivery/analytics/): o2hは、科学者のトラブルシューティングの時間と効率の向上に特に重点を置いているため、4人の化学者ごとに1人の分析科学者の比率で、専用の分析チームを用意しています。 このチームには、マルチプローブのBruker 400 Mhz NMR、LCMS、複数のHPLC/質量分取PREP HPLC、検出器、GC、マイクロ波、およびその他の科学装置が装備されており、高スループットの精製と分析が可能で、24時間年中無休の運用サポートを提供します。この重要な施設のパフォーマンスは毎週監視され、厳格な社内ベンチマークが維持されます。 このベンチマークでは、社内の使用状況の指標だけでなく、業界の主要組織の基準も考慮に入れています。また、プロジェクトの需要に応じて、キャパシティを迅速に追加するための予算を割り当てます。同時に、英国とインドの両方の業者とのサービス契約を維持し、各機器のタイムリーな配送と維持を行っています。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [ip/itの安全性](https://o2h.com/jp/discovery-delivery/ip-it-safety/): o2hは、創薬プロセスの発達段階におけるお客様のIPを保護する責任を理解しています。 o2h IPセキュリティモデルは、プロジェクト中およびその後のお客様のIPを保護するように設計されています。お客様のIPを保護し、お客様がo2hとの既存のコラボレーションに参入、または延長するために必要なレベルの信頼を提供するために、o2hが実施しているIPセキュリティ対策の詳細を記載した白書を用意しました。 この白書では、セットアップ、通信、技術、法的、運用、基盤、人材、文化、および組織的な角度からすべての手順を検証します。このように、プロジェクトのすべてのフェーズにおけるIPの使用と保護にライフサイクルの視点を取り入れました。o2hのプロセスおよび方針は、可能性のあるリスクレベルおよびその重要性に関連して評価されます。方針またはプロセスの実行を保証する責任は明確に識別されています。 主な機能の一部は次のとおりです。 全従業員が署名したCDA（必要なCDAは、お客様とo2hのプロジェクトチーム間で直接実行可能）) MSAに関する先行特許の譲渡 IPプロセスの遵守を確実にするための必須チェック Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [施設と設備](https://o2h.com/jp/discovery-delivery/facilities-equipment/):  o2hの2,000 m2のグリーンフィールドキャンパスは、輸出志向型ユニット（EOU）であり、輸出と工業化を促進するために政府が後援する免税環境です。 私たちのキャンパスには、輸入貨物の事前通関手続き、ゲートでの通関手続きなし、そしてアクセス制御ポイントを備えた安全な建物があります。 ラボユニットの活動は、周囲の研究キャンパス、全面ガラス張りの会議エリア、および地域コミュニティでの作業を支援する社会起業ゾーンによってサポートされています。科学者が精神的にリフレッシュできる環境を作るために、建物には優雅な設計の中庭があります。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [原料とサプライチェーン](https://o2h.com/jp/discovery-delivery/starting-materials-supply-chain/): 原料の迅速な配達は、プロジェクトを早急に開始するために重要であり、創薬と配達のスピードを上げる鍵となります。 専任のスタッフチームには、購買担当者、店舗および在庫担当者、社内税関担当者が含まれます。過去数年の間に、私たちは注文に特化した大規模な販売店のアカウントマネージャーと共に、国内外の販売店のリストを特定しました。私たちは納入基準を評価し、販売店と協力して、原料の納入を継続的に改善します。 供給プロセスは、さまざまな販売店からの予想される納期とともに計画されています。この指標は毎月監視されており、販売店と積極的に連携して、納期のリードタイムを改善しています。また、o2hは最も一般的に使用される化学物質および試薬の在庫を社内で維持し、創薬プロジェクトのスピードをさらにサポートします。 10年以上のこの業界での経験によって、o2hはサプライチェーンのパフォーマンスが総合的なパフォーマンスに与える影響を理解しており、インドの他の競合他社と比較して流れを変えることができるという利点があります。 構造上のアドバンテージ o2hは輸出志向型ユニット（EOU）であり、税関手続きと通関手続きの2つの層全体を排除することにより、化学物質の輸入時間をSEZと比べると短縮できます。 レイヤー1 –輸入貨物の事前通関 SEZでは、ムンバイからアフマダーバードへの積み替え後にのみ税関申告書（BOE）を提出する必要がありますが、EOUでは、ムンバイ空港に着陸する前に、税関職員を通じて輸入貨物の通関手続きを開始するため、2〜3日節約できます。 レイヤー2 –ゲートでの通関なし SEZでは、通関業者がキャンパスのゲートに座っており、科学者に受け渡される前に各貨物を承認する必要があります。この通関手続きは、その業者が多数の会社から同時に貨物を受け取るため、待ち時間が長くなり、最大1〜2日の遅延につながる可能性があります。この問題は、業者が不在の場合にさらに悪化します（例：病気の場合、他の政府の事業に従事しなければならない場合、本人の裁量）。EOUにはそのようなプロセスはありません。 Combi Blocksからの発送で7日間、ARK Pharmaからの発送で5日間、Apollo Scientificからの発送で7日間短縮できます。   プロセスと内部のアドバンテージs 階層の削減により、承認の迅速化（同日、実際には数分）と、化学物質の発注書の同日処理が可能になります。 特に輸入化学物質の注文のために購買チームで働く専用のセカンドシフトは、輸入サプライヤーのタイムゾーンと一致する時間に、化学物質の注文と追跡を行います。 主要な購入プロセスは、化学物質の調達プロセスを理解および最適化するためにマッピングされています。 地元（グジャラート州）および国内（インド）の広範な業者の効率的な利用 化学物質の70％は地元で調達し、 納期はPOの配置から1〜2日です。 主要な国内業者との戦略的関係（Sigma、Alfa Aesar、TCI Indiaそれぞれに保税倉庫があり、化学物質を納税/免税モードで調達するオプションがあります）。 化学物質の17％は国内で調達し、納期は2〜3日（納税注文）または7日（免税注文）です。 配送の通過時間を最小限に抑えるための、Blue-Dart（宅配業者）との戦術的な関係。 米国（Combiblocks等）、英国（Apollo Scientific等）、中国（ARK Pharma等）、ドイツ（Enamine等）などの輸入化学物質の幅広いサプライヤーネットワーク。 o2hでは、階層化されていないセットアップがあり、受注と同じ日に注文を処理して、より迅速な配達を実現しています。 化学物質の13％は国外に調達し、納期は8〜9日（納税注文）または10日（免税注文）です。 配送の通過時間を最小限に抑え、迅速な通関手続きを促進するための宅配業者（DHL、FedExなど）との戦術的な関係。 ムンバイおよびアフマダーバードの専用通関業者（CHA）が、貨物の通関手続きのサポートをします（通関担当官の問い合わせの対応等）。 サプライチェーン対策を含むプロジェクト全体のパフォーマンスに基づいて、インセンティブが与えられるサプライチェーンチーム。 Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [プロセスマッピング](https://o2h.com/jp/discovery-delivery/process-mapping/): o2hは膨大な時間をかけ、組織内のすべてのプロセスをマッピングおよび文書化し、ビジネス開発からグループリーダーやベンチケミストまで、各個人の入力が必要なステップを正確に把握できるようにしています。 最初は集中的なプロセスですが、この決められたプロセス管理は、必要な場合にコミュニケーションやトラブルシューティングの明確な道筋があることを意味します。 また、o2hはプロセスを継続的に監視および更新し、関連性および最適化された状態を保ちます。このプロセスは、社内の科学者とお客様の両方からのフィードバックループの一環であり、お客様の優先事項が満たされ、プロジェクトの各ポイントで正しい成果物が設定されるようにします。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [コミュニケーション](https://o2h.com/jp/discovery-delivery/communication/): お客様とのコミュニケーションは、問題を解決する最も明白で迅速な手段である直接的コミュニケーションから、プロジェクト中に発生するドキュメントやデータを保管するためのイントラネットサイト上のスペースの確保まで、多岐にわたります。 プロジェクト開始時の最初のやり取りでは、お客様との最適な通信プロトコルを特定し、プロジェクト全体で怠りなく実行します。 プロジェクト管理とコミュニケーションの他の通信には、次の方法があります。: プロジェクトステータスレポート 1ページに、プロジェクトの進捗状況をまとめた要約を表にまとめ、潜在的問題を強調し、期限までの進捗状況を追跡します。 o2hダッシュボードパフォーマンスメトリック o2hは、幅広いパフォーマンスデータも記録しています。これは隔週で安全なウェブサイトにアップロードされます。 プロジェクトフィードバックフォーム プロジェクトのフェーズごとの終わりに、o2hはお客様にフィードバックフォームに記入するようにお願いします。フィードバックフォームは、o2hのサービス改善に役立つ客観的な情報を提供します。このデータは照合、分析され、o2hのすべてのシニアレベルの専門家に配布されます。 Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [プロジェクト管理](https://o2h.com/jp/discovery-delivery/project-management/): 発見のスピードは、o2hにおけるすべてのプロジェクト管理の中核です。効果的なプロジェクト管理とコミュニケーションは、プロジェクトの有益な相互作用と前向きな結果を保証するための不可欠な要素です。o2hは、統計的な日々のレポートと最も効果的な方法での科学的進歩の測定を可能にする、シンプルで明確なテンプレートを、長年にわたって完成させてきました。 パフォーマンスと生産性の指標は、o2h運用モデルの基盤です。指標は、o2hの内部プロジェクト管理システムに従って毎週更新されます。データは可能な場合はグラフ形式で表され、内部だけでなくお客様とも共有されます。o2hは、生産性と配信パフォーマンスを向上させるために、20の「ダッシュボード指標」の包括的なシステムを導入しました。これらのダッシュボード指標により、継続的な改善サイクルを通じてパフォーマンスを分析および最適化できます。 o2hは、FTE、プロジェクト、一カ月、四半期レベルごとに、化合物のさまざまな指標を注視します。例えば、合成の指標には、試験反応の数、成功した反応、精製、ステップ数、最終化合物、反応またはステップあたりの平均時間、化合物ごとの期限変更の数、化合物ごとの遅延、化合物の配送が遅延する理由の分類、さらにステータスレポートと発送の適時性も含まれます。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [完全な研究所サービスユニット](https://o2h.com/jp/discovery-delivery/full-lab-service-units/): o2hでの化学は、120名以上の従業員を収容できる6つのラボユニットを備えた特注の最先端グリーンフィールドキャンパスで行われます。 各ラボユニットは、IP/ITで保護された広々としたモジュールで、8つのドラフトとそれに付随する書き込みエリアがあります。この設計のモジュール性により、高レベルのセキュリティとともに化学者に快適な作業領域を提供し、お客様の体験をカスタマイズすることができます。すべてのラボユニットは、キーカードでのみアクセスでき、統合されたエンジニアリングおよび中央サービスサポートの恩恵を受けることができます。 当社のキャンパスは、安全な運用の最高水準と、極端なインドの気候条件での開発研究活動に適用可能な、最新の実証済み、もしくは実験的な環境思考を取り入れています。これらの機能の一部に、LUX、モーションコントローラー、低エネルギー自然冷却器などがあります。 ラボユニットでは、ドラフトは消火器でVAV制御されています。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [高速配送](https://o2h.com/jp/discovery-delivery/high-speed-delivery/): デリバリーモデルは、効果的なプロジェクト管理、プロセスと機器、および人員のスピードを考慮して設計されています。 安全性の高い実験棟では、国境を越えたコラボレーションの経験を持っている熟練の専門プロジェクトチームとの確立した運用プロセスが完全に備えられており、費用対効果の高い24時間高速創薬に着手する準備ができています。 インドでの事業の効果は、物流、コミュニケーション、客観的なプロジェクト管理サポートを提供する英国のプロジェクトオフィス（ケンブリッジ）によって後援されています。 o2hは、徹底したコミュニケーションと迅速な意思決定に基づく分子の早期かつ集中的な評価が、成功したドラッグ・ライク化合物の高スループットにつながることを理解しています。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [discovery-delivery](https://o2h.com/jp/discovery-delivery/): 革新への情 熱 私たちは、従業員、プロジェクト管理、技術モデルを常に革新し、共同研究者に優れた結果をもたらしています。世界初のアプリベースのテクノロジープラットフォームChemistry in the CloudTMによって、協力してより迅速な意思決定を行うことができます。科学の真の洞察に基づいた、ターゲット分子の早期かつ集中的な評価は、より迅速な流通の実行につながります。その結果、成功した医薬品候補化合物のスループットが向上します。.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [証明書](https://o2h.com/jp/discovery-collaborators/testimonial/): o2hは、共同研究者の推薦状によってビジネスを成長させてきたため、皆様にも少しでも貢献したいと考えております。創薬プロジェクトでコラボレーターに連絡し、当社との連携を希望している場合は連絡をお待ちしております。 「o2hは過去10年間、創薬活動をサポートしてきました！現在進行中の共同コラボレーション契約の一環として、…、初のマイルストーン支払いでo2hを受賞できたことを嬉しく思います。」 英国のバイオテック 「o2hとのコラボレーションは順調に進んでおり、2015年8月に化学の研究を開始して以来、最近の進歩がシリーズの勢力を100倍に押し上げています。チーム間のコラボレーションをさらに発展させることを楽しみにしています！」 スウェーデンのバイオテック 「o2hは、仮想バイオテクノロジー企業に不可欠な投資から開発活動までのスピンアウトに貢献してきました。彼らの投資とリスク共有のビジネスモデルは革新的であり、小規模な新興企業として非常に役立ち、私たちのニーズに対応してくれました。」 英国のバイオテック 「o2hは迅速に対応し、会社をサポートするためにあらゆる必要な物で私たちの開発の取り組みをサポートしてくれています。彼らは柔軟性があり、能力は合成以上のものがあります。高く評価できるコラボレーターです。」 イスラエルのバイオテック 「新しい旗の下で働いている今、o2hと共に作業できて非常に幸せです。o2hのチームのエネルギーと努力のおかげで、プロジェクトが非常に急速に進み、刺激的な新しいテクノロジーを構築しています。すべてに感謝しています！」 米国のバイオテック 「o2hは、非常に専門的な方法で開発の取り組みをサポートし、高いクオリティで迅速に提供して頂きました。また、費用対効果も非常に優れていました。」 イスラエルのバイオテック Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [フィードバック](https://o2h.com/jp/discovery-collaborators/feedback/): 継続的な改善は、o2hで実行されるすべての作業の中心的な志であり、これはお客様のフィードバックが中心的な役割を果たしているという成長過程の貴重な部分です。お客様のフィードバックは、従業員ボーナスの要素として社内で使用されます。 詳細なお客様のフィードバックフォームは、各プロジェクトの終了時、または長期プロジェクトの場合は年末に送信されます。このフィードバックフォームからの回答は、プロジェクト開始フォームで設定されたプロジェクトの優先順位に照らして分析され、この分析に基づいてお客様と話し合い、お客様の満足度を確約します。長期プロジェクトの場合、すべての利害関係者が優先事項を再検討し、効果的な研究目標を設定し再定義する機会でもあります。 当社のコミュニケーションは、プロジェクトの潜在的な課題を明らかにし、すぐに修正措置を講じるように調整されています。お客様のフィードバックフォームで問題が特定された場合、チームで分析を行い、この経験から学び、是正措置を講じ、将来のプロジェクトでの失敗を未然に防ぎます。お客様のフィードバックフォームは、従業員とo2hの強みを継続的に学習、改善、成長させるためのスタンドアロンの演習ではなく、運用プロセスの一部として扱われます。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [プロジェクトの開始](https://o2h.com/jp/discovery-collaborators/project-initiation/): お客様の優先順位をよく理解し迅速なスタートを切ることは、o2hでの創薬プロジェクトに不可欠な2つの特徴です。 プロジェクトの開始プロセスはビジネス開発から始まり、経営者が科学およびその他のプロジェクトの優先順位を各コラボレーターと決定し、プロジェクトリーダーに伝達します。チームとの最初の共同研究者会議では、化合物の優先順位、配送スケジュール、通信形式と配送、専用イントラネットプロジェクトサイトへのアクセスなどの詳細がアンケートに入力されます。これらの詳細は、o2hでのすべての共同研究者との協力におけるコアとなります。 すべての共同研究者の開始データは、プロジェクトチームの割り当てとプロジェクトチーム紹介フォームのメール送信を含む内部プロセスと組み合わされており、早期開始指標の一部になっております。この指標は毎月o2hで収集および評価され、各プロジェクトの正しい開始を記録し保証します。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [discovery-collaborators](https://o2h.com/jp/discovery-collaborators/): 革新への情 熱 私たちは、従業員、プロジェクト管理、技術モデルを常に革新し、共同研究者に優れた結果をもたらしています。世界初のアプリベースのテクノロジープラットフォームChemistry in the CloudTMによって、協力してより迅速な意思決定を行うことができます。科学の真の洞察に基づいた、ターゲット分子の早期かつ集中的な評価は、より迅速な流通の実行につながります。その結果、成功した医薬品候補化合物のスループットが向上します。.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [統合創薬](https://o2h.com/jp/discovery-biology/integrated-drug-discovery/): 統合創薬（IDD）プロジェクトの成功を測定するための究極の測定基準は、知的財産とお客様への価値を生み出す能力です（in vitro条件下で低いnM活性を示し、病態生理学的に関連する疾患モデルにおいて統計的に有意なin vivo有効性を示すリード化合物の同定など）。 成功したIDDプロジェクトは、さまざまな分野の効率的な統合、医薬品化学の経験、優れた運用、実用的なアプローチに依存しています。o2hは、IDDサービスを確立する際にモジュール方式を採用しており、お客様にアウトソーシングの決定において最大の柔軟性を提供しています。 創薬プロセスのさまざまなモジュールは、サービスのサブセットに唯一のエントリーポイントとして個別に、またはヒットの特定からリード化合物の創出までの従来の創薬手法として利用できます。当社の専門知識には、医薬品化学、ヒット同定、リード生成/最適化、計算化学、in vitro酵素および細胞ベースのスクリーニング、DMPKおよび複数の治療分野におけるin vivoモデルが含まれます。o2hには動物施設がありません。PK研究のin lifeフェーズとin vivo有効性研究は、過去数年間、私たちが好ましい関係にあるCROと共に行われます。 o2hは、インドの複数のCROと戦略的提携があり、化学プロセスのスケールアップと開発（GMPと非GMP）、生物分析研究、製剤アプローチ、安全性薬理学および毒物学研究、臨床試験用品、および医療文書を通じて、顧客がINDアプリケーション段階にプロジェクトを進めることを支援します。詳細については、info@o2h.com までお問い合わせください。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [in vivo研究](https://o2h.com/jp/discovery-biology/in-vivo-studies/): o2hは、標準的なバイオアベイラビリティ/組織分布PK研究、急性/慢性毒性学研究、および複数の治療適応症の病態生理学的に関連する実験モデルの実施に関する深い専門知識を持っています。 巨視的観察は、病理組織学的分析、血液学的および生化学的パラメータの推定など、さまざまな異なる技術で確証することができます。現在、in vivo実験はげっ歯類（マウス、ラットなど）でのみ行われています。当社のin vivoモデルは、診療ごとの個別支払形式で利用できるほか、統合生物学プロジェクトの一部としても利用できます。お客様の要件に応じて、これらのモデルをカスタマイズすることもできます。In vivo研究は、o2hがこの数年間好ましい関係にあるCROと共同で行われます。 生体内モデルの例 コラーゲン誘発関節炎 アジュバント誘発関節炎 DSS誘発大腸炎 TNBS誘発大腸炎 PMAによる乾癬/アトピー性皮膚炎 IMQ誘発性乾癬/アトピー性皮膚炎 サイトカイン放出アッセイ 単回投与急性毒性 反復投与毒性試験 経口バイオアベイラビリティ研究 Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [In vitroアッセイ](https://o2h.com/jp/discovery-biology/in-vitro-assays/): o2hのin vitro施設は、当社の化学の顧客に迅速な意思決定ポイントを提供するために開発されました。 化合物の活性や潜在的な問題点を評価するための薬理学サービスの範囲を含めるために、規模と能力を倍増しました。当社の専用の研究室には、さまざまな治療領域での生化学または細胞アッセイの開発と最適化に役立つ、蛍光、ルミネセンス、および吸光度の業界標準フォーマットが含まれています。 o2hは以下のアッセイを提供します: ADMEアッセイ 溶解度 (熱力学、速度論)、Log P/Log D研究、透過性 (PAMPA)、CYP阻害 (蛍光、LCMS/MSベース)、ミクロソーム安定性、血漿安定性、肝細胞安定性、血漿タンパク質結合。 ターゲットベースのアッセイ 酵素/キナーゼアッセイ、結合アッセイ、GPCRアッセイ 細胞ベースのアッセイ ELISA、増殖/細胞毒性、リン酸化状態、hPBMCを使用したサイトカイン産生アッセイ、シグナル伝達アッセイ。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [discovery-biology](https://o2h.com/jp/discovery-biology/): 革新への情 熱 私たちは、従業員、プロジェクト管理、技術モデルを常に革新し、共同研究者に優れた結果をもたらしています。世界初のアプリベースのテクノロジープラットフォームChemistry in the CloudTMによって、協力してより迅速な意思決定を行うことができます。科学の真の洞察に基づいた、ターゲット分子の早期かつ集中的な評価は、より迅速な流通の実行につながります。その結果、成功した医薬品候補化合物のスループットが向上します。.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [ADMEスクリーニングサービス](https://o2h.com/jp/discovery-biology/adme-screening-services/): o2hのin vitro施設は、ADME（吸収、分布、代謝、排泄）によって、創薬プログラムをサポートするために、当社の化学クライアントまたはスタンドアロン製品に、より迅速で改善された意思決定ポイントを提供します。 ADMEパラメータに対するクライアントの要件に応じて、コスト効率の高い標準化およびカスタマイズされたアッセイを提供します。ADMEの機能は次のとおりです。: ADMEアッセイ- 物理化学的スクリーニング 水溶性 (熱力学および速度論) Log P Log D 薬物代謝 ミクロソーム安定性 プラズマ安定性 肝細胞安定性 タンパク質結合 血漿タンパク質結合 透過性 PAMPA 薬物間相互作用 CYP阻害アッセイ (蛍光およびLCMS/MS) Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [抗体薬物複合体](https://o2h.com/jp/discovery-chemistry/antibody-drug-conjugate/): ADCの特注中間体  小分子創薬プログラムをサポートするための専門知識に基づき、以下に概説するように、ADC分野のプロジェクトにサービス提供を拡大しました。 私たちは、特注のリンカー、リンカー試薬、試薬、ペプチド骨格、および関連する中間体の合成、開発、およびスケールアップをサービスとして行っており、R&Dのニーズに対応するコラボレーターの仕様に対応しています。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [discovery-chemistry](https://o2h.com/jp/discovery-chemistry/): 革新への情 熱 私たちは、従業員、プロジェクト管理、技術モデルを常に革新し、共同研究者に優れた結果をもたらしています。世界初のアプリベースのテクノロジープラットフォームChemistry in the CloudTMによって、協力してより迅速な意思決定を行うことができます。科学の真の洞察に基づいた、ターゲット分子の早期かつ集中的な評価は、より迅速な流通の実行につながります。その結果、成功した医薬品候補化合物のスループットが向上します。.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [jp](https://o2h.com/jp/): 革新への情 熱 私たちは、従業員、プロジェクト管理、技術モデルを常に革新し、共同研究者に優れた結果をもたらしています。世界初のアプリベースのテクノロジープラットフォームChemistry in the CloudTMによって、協力してより迅速な意思決定を行うことができます。科学の真の洞察に基づいた、ターゲット分子の早期かつ集中的な評価は、より迅速な流通の実行につながります。その結果、成功した医薬品候補化合物のスループットが向上します。.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [ケミカルバイオロジー](https://o2h.com/jp/discovery-chemistry/chemical-biology/): 近年、o2hはターゲットの検証とメカニズムの理解にプラスの影響を与えるオーダーメイドの高品質ツールを提供するために、複数のケミカルバイオロジープロジェクトをサポートする機能を拡張しました。 これには、最も効率的な方法で複雑な分子を調整するための最適化された構築方法の開発とともに、重要である多種多様な中間体を準備する最先端の研究が含まれます。 これらのツールが必要とされている化合物の仕様を満たし、高品質の生物学的データを提供するための最も適切な方法で得られていることを保証する事に関して、私たちの分析グループは重要な役割を果たします。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [計算化学 -](https://o2h.com/jp/discovery-chemistry/computational-chemistry/): o2hの計算化学者は、in silicoベースのスクリーニングプロジェクトおよび医薬品化学プロジェクトのサポートにより、顧客にスタンドアロンサービスを提供することに取り組んでいます。計算化学の専門知識には、分子モデリング、バーチャルスクリーニング、およびドラッグデザインが含まれます。 バーチャルスクリーニングのサービスでは、ターゲットの特定、in silicoの医薬品類似性、顧客および商用データベースのスクリーニングによる、集中的なリードおよびヒット化合物の同定、in vitro研究のヒットを優先するドッキング研究が含まれます。 ヒットの生成とリードの最適化をサポートするドラッグデザインを適用して、医薬品化学デザインの取り組みを強化し、構造修正を進め、効能、選択性、薬物様の特性を強化します。私たちの分子モデラーと医薬品化学者の間の連携は、このプロセスで重要な役割を果たします。 これらとは別に、ターゲットに焦点を当てたライブラリの設計、ターゲットのモデリング、分子動力学シミュレーション、およびターゲットと治療領域に基づく高度に予測可能な3D-QSARモデルの開発もサポートします。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [医薬品化学 -](https://o2h.com/jp/discovery-chemistry/medicinal-chemistry/): o2hで利用可能な医薬品化学の専門知識には、ヒットの特定、ヒットからリードへの最適化、リードの生成、およびリードの最適化が含まれます。これらはすべて、独立した、または統合された創薬プロジェクトの一部としてアクセスできます。 ヒット識別/リード生成プロジェクトには、顧客の希望するターゲットのリガンド設計、同族列または多種多様な化合物の合成、構造が関連する化合物の設計と生成、一般的および専門的なライブラリのコンビナトリアル合成、および核となる化合物骨格の代用物の検索が含まれます。 Hit-to-Leadプロジェクトは通常、真の構造活性相関（SAR）の確認と構造的または薬理学的な障害の削減を行います。o2hは、お客様がADMEおよびin vitro生物活性（一次および二次スクリーニング）についてこれらの化合物を迅速にスクリーニングできるように、十分量の小さな集束アレイの化合物を合成する機能を備えています。 リード最適化フェーズにプロジェクトを進める場合、目的のターゲット製品のプロファイルに充分一致する化合物を生成するために、o2hの化学者は生物学の担当者と集中的に作業します。これには通常、先行技術の徹底的な調査と特許性の保証、バックアップシリーズの生成、および化合物のin vivo概念実証への誘導が含まれます。私たちの生物学者は、特定の人間の病的状態を再現するin vivo実験モデルの生成、PK/PD、毒物学およびその他の関連する薬理学的研究の設計と効率的な実行を支援し、これらの化合物の開発をさらに前進させることができます。Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [有機化学 -](https://o2h.com/jp/discovery-chemistry/organic-chemistry/): o2hは、mg/gスケールでの開発化学において非常に高い評価を受けているサービスプロバイダーです。私たちは、ヨーロッパ、アメリカ、日本からの有名な製薬およびバイオテクノロジー企業と提携しています。 o2hの専門チームは、必要な高品質仕様を備えた小分子NCEの調製において、幅広い経験を持っています。これは、単一、多段階、小さなアレイ、およびフォーカスされたライブラリの合成を含む、本来の方法の利用に習熟しています。私たちの科学チームは、ヒットからリードまでとリード化合物の最適化プロジェクトで使用するための、フォーカスされたライブラリの並行構築の経験も豊富です。 すべての化合物の配送には、高磁場NMR、質量およびLC-MS/HPLC/GCによる純度を含む完全な特性データを付属しています。 SciFinderやBeilsteinなどのデータベースへのアクセスすることにより、チームに新しい合成ルートを変更および開発するために必要なすべての情報を提供します。 o2hは、次のような幅広い化学に関する経験があります: キラル化学 脂肪族、芳香族、複素環化学 炭水化物化学 ペプチド化学 ステロイド化学 ヌクレオシド化学 コンビナトリアルケミストリー 天然物化学 フラグメントライブラリ 代謝物/不純物/レファレンス合成 マイクロ波化学 Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Request a demo by mail…](https://o2h.com/request-a-demo-by-mail/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [thank you for demo request](https://o2h.com/thank-you-for-demo-request/): Thank you for requesting a demo. Our team will get back to you shortly with next steps. In case if you have any questions, please feel free to reach us at info@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Login](https://o2h.com/login/): [ultimatemember form_id=””]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Contact us thank you](https://o2h.com/thank-you-for-contacting/): In case if you have any queries, please do not hesitate to get in touch with us at info@o2h.com Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Chemistry in the Cloud](https://o2h.com/chemistry-in-the-cloud/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Makesense upcoming features](https://o2h.com/makesense-upcoming-features/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [redirect](https://o2h.com/redirect/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Thank you!](https://o2h.com/top-up-successfull/): Account Number 36261 Account Name Reyker Securities plc client a/c re o2h ventures Account Sort Code 60-00-01 or you can pay by cheque Payable to Reyker Securities plc, a/c re o2h Ventures Post to Reyker Securities plc, 17 Moorgate, London EC2R 6AR Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Top-up your Subscription](https://o2h.com/top-up-your-subscription/): Enter the amount below to top-up your Subscription into the Fund.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [email](https://o2h.com/email/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [GetQuote](https://o2h.com/getquote/)
- [Thank you for registering with us..](https://o2h.com/register-advisor/thank-you/): We have also sent you an activation link included in the same email as the information memorandum which will allow you to login and continue the on-boarding processes.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Thank you for registering with us..](https://o2h.com/register-as-an-investor/thank-you/): We have also sent you an activation link included in the same email as the information memorandum which will allow you to login and continue the on-boarding processes.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [o2h Therapeutics and AI EIS Fund. Enterprise Investment Scheme.](https://o2h.com/ventures/): passion for EIS investing Large pharmaceutical companies have been closing down research centres globally for the last decade. This shift in focus of the large pharmaceutical companies has moved them from developing innovation in-house to acquiring innovation externally, forcing us prices for the best science and providing earlier exit opportunities. The team at o2h have access to the most exciting scientific ideas in the through its live working relationships fostered over many years working as a discovery services company giving it far earlier access than competitors to the most promising companies. Early stage companies often need more than just money, […]
- [Register](https://o2h.com/register-advisor/): [ultimatemember form_id=”1116″]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Register with us](https://o2h.com/register-as-an-investor/): [ultimatemember form_id=”1151″]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Password Reset](https://o2h.com/password-reset/): [ultimatemember_password] Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Account](https://o2h.com/account/): [ultimatemember_account]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Logout](https://o2h.com/logout/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Members](https://o2h.com/members/): [ultimatemember form_id=1057]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Register](https://o2h.com/register/): [ultimatemember form_id=1054]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [User](https://o2h.com/user/): [ultimatemember form_id=1056]Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [invester form](https://o2h.com/invester-form/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Congratulations!](https://o2h.com/verification-success/): Account Number 48761273 Account Name Reyker Securities plc client a/c re o2h ventures Account Sort Code 60-00-01 Access Number 36261 Please include your Reference Number and Access Number when transferring Funds. or you can pay by cheque, please write your Reference Number and Access Number on the reverse. Payable to Reyker Securities plc, a/c re o2h Ventures Post to Reyker Securities plc, 17 Moorgate, London EC2R 6AR Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [invest-verification](https://o2h.com/invest-verification/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [set-password](https://o2h.com/set-password/): Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [404 page](https://o2h.com/404-page/): The page you are looking for is no longer here. May be it was never here in the first place in any case, we are sorry you were sent on this wild goose chase. Go home Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative
- [Community](https://o2h.com/community/): The approach is quite simple, we understand that we have a contribution to make to the community in which we do our work, not at some unspecified point in the future, but now, and as part of our life journey, however small that contribution is. o2h group encourages contribution, partnerships and connections with local NGO’s and the community. o2h group takes its work in the community seriously. The first stage is always to establish a personal connection based not on solving anyone’s problems, but of giving of ones love, time and energy. The second stage is to explore ways in […]
- [Culture](https://o2h.com/careers/culture-values/culture/): The DNA of o2h group is centred around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners.  Our set of values are centred around the speed at which we learn, innovation, teamwork, attention to detail, energy, delivery, integrity, and community.Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative


[comment]: # (Generated by Hostinger Tools Plugin)